| 1 | VCd versus VRd in Newly Diagnosed Multiple Myeloma: Matched Real-World Analysis from the Balkan Myeloma Study Group (BMSG) | 0.8 | 2 | Citations (PDF) |
| 2 | Precision medicine in gynecological cancer (Review) | 1.3 | 20 | Citations (PDF) |
| 3 | Disease Characteristics and Treatment Outcomes of Myeloma Patients Under 50 Years of Age: An Analysis of the Balkan Myeloma Study Group | 0.8 | 1 | Citations (PDF) |
| 4 | Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM Trial | 1.5 | 8 | Citations (PDF) |
| 5 | Long-Term Survivor with Paraneoplastic Cerebellar Ataxia and Small-Cell Lung Cancer | 1.8 | 0 | Citations (PDF) |
| 6 | Evaluating Minimal Residual Disease Negativity as a Surrogate Endpoint for Treatment Efficacy in Multiple Myeloma: A Meta‐Analysis of Randomized Controlled Trials | 5.2 | 30 | Citations (PDF) |
| 7 | Evaluation of Clinical Characteristics and Prognostic Factors of Early Progressive Disease (EPD) in Newly Diagnosed Multiple Myeloma Patients: Real-World Data of the Greek Myeloma Study Group | 0.8 | 1 | Citations (PDF) |
| 8 | Possible Prognostic Role of BMI Before Chemotherapy in the Outcomes of Women with Ovarian Cancer | 3.2 | 2 | Citations (PDF) |
| 9 | PARP inhibitors during conception and pregnancy in breast cancer | 3.5 | 5 | Citations (PDF) |
| 10 | Report of Consensus Panel 5 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors | 2.3 | 4 | Citations (PDF) |
| 11 | Efficacy and safety of isatuximab monotherapy to treat relapsed or refractory multiple myeloma: a pooled analysis of clinical trials | 1.0 | 3 | Citations (PDF) |
| 12 | Molecular Prognostic Factors in Uterine Serous Carcinomas: A Systematic Review | 2.0 | 4 | Citations (PDF) |
| 13 | Predictive value of free light chain burden in patients with AL amyloidosis treated with bortezomib-based regimens | 3.7 | 12 | Citations (PDF) |
| 14 | The Role of the Bone Marrow Microenvironment in Physical Function and Quality of Life in Patients with Multiple Myeloma After First-Line Treatment with Novel Agents and Autologous Transplantation | 0.6 | 3 | Citations (PDF) |
| 15 | A prospective study of small fiber neuropathy in AL amyloidosis | 2.6 | 2 | Citations (PDF) |
| 16 | EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma | 1.7 | 10 | Citations (PDF) |
| 17 | Monoclonal gammopathy of undetermined significance in patients with solid tumours: Effects of immune checkpoint inhibitors on the monoclonal protein | 1.7 | 0 | Citations (PDF) |
| 18 | Cystatin C as Biomarker for the Evaluation of Renal Outcome in AL Amyloidosis | 5.2 | 3 | Citations (PDF) |
| 19 | Observation or treatment for smoldering multiple myeloma? A systematic review and meta-analysis of randomized controlled studies | 4.1 | 9 | Citations (PDF) |
| 20 | Semiquantitative Analysis in PET/CT Imaging of Prostate Cancer | 1.8 | 3 | Citations (PDF) |
| 21 | Characteristics and Survival Outcomes of Solitary Plasmacytomas: A 30‐Year Experience of the Greek Myeloma Study Group on 175 Patients | 5.2 | 6 | Citations (PDF) |
| 22 | Upfront Anti-CD38 Monoclonal Antibody-Based Quadruplet Therapy for Multiple Myeloma: A Systematic Review and Meta-Analysis of Clinical Trials | 2.7 | 6 | Citations (PDF) |
| 23 | Second Primary Malignancies and Disease Transformation in Patients With Symptomatic Waldenström’s Macroglobulinemia | 0.8 | 2 | Citations (PDF) |
| 24 | The impact of high-risk cytogenetics on treatment efficacy and outcomes of patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis of randomized controlled trials | 3.7 | 5 | Citations (PDF) |
| 25 | EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma | 54.3 | 144 | Citations (PDF) |
| 26 | Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions | 2.4 | 3 | Citations (PDF) |
| 27 | Pomalidomide, Cyclophosphamide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Single-Center Experience | 0.8 | 3 | Citations (PDF) |
| 28 | Prevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma Network | 0.6 | 6 | Citations (PDF) |
| 29 | Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment | 0.8 | 6 | Citations (PDF) |
| 30 | Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA | 5.2 | 17 | Citations (PDF) |
| 31 | Thrombotic and bleeding complications in patients with AL amyloidosis | 1.7 | 8 | Citations (PDF) |
| 32 | Efficacy and immune modulation associated with the addition of IMiDs to Daratumumab backbone in multiple myeloma patients refractory to both drug classes: resetting synergistic activity | 4.1 | 3 | Citations (PDF) |
| 33 | A 74-Year-Old Man With Waldenström Macroglobulinemia and Progressive DyspneaChest, 2024, 165, e39-e43 | 0.8 | 2 | Citations (PDF) |
| 34 | Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison | 1.0 | 4 | Citations (PDF) |
| 35 | Unraveling the Role of the NLRP3 Inflammasome in Lymphoma: Implications in Pathogenesis and Therapeutic Strategies | 3.2 | 11 | Citations (PDF) |
| 36 | Retinopathy in a Patient With IgM MGUS: Causal Association or an Epiphenomenon? | 0.8 | 1 | Citations (PDF) |
| 37 | Small RNA‐seq and clinical evaluation of tRNA‐derived fragments in multiple myeloma: Loss of mitochondrial i‐tRFHisGTG results in patients' poor treatment outcome | 1.7 | 10 | Citations (PDF) |
| 38 | An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study | 1.0 | 15 | Citations (PDF) |
| 39 | Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma | 2.1 | 5 | Citations (PDF) |
| 40 | Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow‐up subgroup analysis of the BOSTON trial | 1.5 | 13 | Citations (PDF) |
| 41 | Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma | 5.2 | 8 | Citations (PDF) |
| 42 | ciRS‐7 circular RNA overexpression in plasma cells is a promising molecular biomarker of unfavorable prognosis in multiple myeloma | 0.9 | 7 | Citations (PDF) |
| 43 | Low circulating tumor cell levels correlate with favorable outcomes and distinct biological features in multiple myeloma | 5.2 | 15 | Citations (PDF) |
| 44 | Ectopic Cushing syndrome in metastatic castration‑resistant prostate cancer: A case report and review of literature | 1.1 | 3 | Citations (PDF) |
| 45 | The Prognostic Role of BRD4 Expression in High-Grade Serous Ovarian Cancer | 2.7 | 3 | Citations (PDF) |
| 46 | The Interplay between the DNA Damage Response (DDR) Network and the Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in Multiple Myeloma | 3.2 | 13 | Citations (PDF) |
| 47 | Central nervous system multiple myeloma: A real‐world multi‐institutional study of the Greek Myeloma Study Group | 5.2 | 20 | Citations (PDF) |
| 48 | Necrotizing Laryngitis in Patients with Hematologic Disease: The First Case-Report Due to PDR Acinetobacter baumannii and Literature Review | 2.7 | 0 | Citations (PDF) |
| 49 | An open‐label, first‐in‐human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma | 1.5 | 2 | Citations (PDF) |
| 50 | Trabecular Bone Score as a Complementary Tool for the Assessment of Bone Mineral Density in Patients with Asymptomatic Monoclonal Gammopathies | 1.8 | 2 | Citations (PDF) |
| 51 | Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies | 2.1 | 14 | Citations (PDF) |
| 52 | Integrated Network-Based Analysis of Diseases Associated with Amyloid Deposition Through a Disease–Protein–Drug Network | 3.3 | 1 | Citations (PDF) |
| 53 | Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma: Prognostic and More | 12.4 | 17 | Citations (PDF) |
| 54 | Pulmonary function tests reveal unrecognised lung dysfunction and have independent prognostic significance in patients with systemic AL amyloidosis | 2.6 | 0 | Citations (PDF) |
| 55 | Clinical usefulness of testing for severe acute respiratory syndrome coronavirus 2 antibodies | 2.4 | 14 | Citations (PDF) |
| 56 | Serological testing for SARS-CoV-2: Advancements and future challenges | 2.4 | 8 | Citations (PDF) |
| 57 | Pembrolizumab in combination with bevacizumab and oral cyclophosphamide in heavily pre-treated platinum-resistant ovarian cancer | 2.2 | 11 | Citations (PDF) |
| 58 | What to expect from paraneoplastic syndromes of the nervous system in uterine cancer: A review of the literature | 0.4 | 5 | Citations (PDF) |
| 59 | A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma | 4.1 | 2 | Citations (PDF) |
| 60 | Monoclonal Gammopathy of Thrombotic Significance | 2.7 | 29 | Citations (PDF) |
| 61 | The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018 | 4.1 | 52 | Citations (PDF) |
| 62 | Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy | 4.1 | 18 | Citations (PDF) |
| 63 | Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab‐based quadruplets: A multicenter study by the Greek myeloma study group | 5.2 | 28 | Citations (PDF) |
| 64 | Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study | 2.2 | 14 | Citations (PDF) |
| 65 | Proteasome Inhibitor-Based Regimens in the Frontline Management of Waldenström Macroglobulinemia | 1.5 | 4 | Citations (PDF) |
| 66 | Metaplastic Carcinoma of the Breast: Case Series of a Single Institute and Review of the Literature | 2.1 | 13 | Citations (PDF) |
| 67 | Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN) | 3.7 | 48 | Citations (PDF) |
| 68 | Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study | 4.1 | 86 | Citations (PDF) |
| 69 | Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study | 3.7 | 96 | Citations (PDF) |
| 70 | Prognostic impact of translocation t(11;14) and of other cytogenetic abnormalities in patients with AL amyloidosis in the era of contemporary therapies | 1.5 | 14 | Citations (PDF) |
| 71 | Impact of CDK4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant Setting | 0.9 | 12 | Citations (PDF) |
| 72 | Intravenous rituximab and oral cyclophosphamide for the treatment of cancer‑associated retinopathy in a patient with epithelial ovarian cancer: A case report | 1.1 | 5 | Citations (PDF) |
| 73 | Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial Subanalysis | 0.8 | 2 | Citations (PDF) |
| 74 | Optimal Time Interval between Neoadjuvant Platinum-Based Chemotherapy and Interval Debulking Surgery in High-Grade Serous Ovarian Cancer | 2.7 | 7 | Citations (PDF) |
| 75 | Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study | 12.4 | 108 | Citations (PDF) |
| 76 | Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma | 3.2 | 15 | Citations (PDF) |
| 77 | Association of Selinexor Dose Reductions With Clinical Outcomes in the BOSTON Study | 0.8 | 10 | Citations (PDF) |
| 78 | Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era | 2.1 | 5 | Citations (PDF) |
| 79 | MYD88 Wild Type in IgM Monoclonal Gammopathies: From Molecular Mechanisms to Clinical Challenges | 0.4 | 2 | Citations (PDF) |
| 80 | Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial | 2.7 | 4 | Citations (PDF) |
| 81 | EPH/Ephrin Signaling in Normal Hematopoiesis and Hematologic Malignancies: Deciphering Their Intricate Role and Unraveling Possible New Therapeutic Targets | 2.7 | 5 | Citations (PDF) |
| 82 | Metabolomics Point out the Effects of Carfilzomib on Aromatic Amino Acid Biosynthesis and Degradation | 3.2 | 3 | Citations (PDF) |
| 83 | Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients | 3.7 | 19 | Citations (PDF) |
| 84 | Tenofovir-Induced Fanconi Syndrome Presenting with Life-Threatening Hypokalemia: Review of the Literature and Recommendations for Early Detection | 1.8 | 5 | Citations (PDF) |
| 85 | Utilization and tolerance of beta-blockers among patients with AL amyloidosis | 2.6 | 11 | Citations (PDF) |
| 86 | Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics | 1.5 | 9 | Citations (PDF) |
| 87 | SARS-CoV-2 wastewater surveillance data can predict hospitalizations and ICU admissions | 5.6 | 204 | Citations (PDF) |
| 88 | Late‐onset hematological complications post COVID‐19: An emerging medical problem for the hematologist | 5.2 | 57 | Citations (PDF) |
| 89 | Nonselective proteasome inhibitors in multiple myeloma and future perspectives | 1.9 | 11 | Citations (PDF) |
| 90 | Determination of MYD88L265P mutation fraction in IgM monoclonal gammopathies | 3.7 | 16 | Citations (PDF) |
| 91 | Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study | 16.1 | 155 | Citations (PDF) |
| 92 | Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial | 4.1 | 20 | Citations (PDF) |
| 93 | The Mutational Landscape of Early-Onset Breast Cancer: A Next-Generation Sequencing Analysis | 1.7 | 14 | Citations (PDF) |
| 94 | Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning Analysis | 2.5 | 8 | Citations (PDF) |
| 95 | The Cytogenetic Profile of Primary and Secondary Plasma Cell Leukemia: Etiopathogenetic Perspectives, Prognostic Impact and Clinical Relevance to Newly Diagnosed Multiple Myeloma with Differential Circulating Clonal Plasma Cells | 2.5 | 21 | Citations (PDF) |
| 96 | How I treat relapsed multiple myelomaBlood, 2022, 139, 2904-2917 | 3.6 | 48 | Citations (PDF) |
| 97 | Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapyBlood, 2022, 139, 1409-1412 | 3.6 | 35 | Citations (PDF) |
| 98 | Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus | 3.2 | 53 | Citations (PDF) |
| 99 | Persisting Endothelial Cell Activation and Hypercoagulability after COVID-19 Recovery—The Prospective Observational ROADMAP-Post COVID-19 Study | 0.4 | 9 | Citations (PDF) |
| 100 | Health‐related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient‐reported outcomes from the APOLLO trial | 5.2 | 10 | Citations (PDF) |
| 101 | DUPLICATE: Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma | 0.8 | 0 | Citations (PDF) |
| 102 | Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma | 0.8 | 44 | Citations (PDF) |
| 103 | Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222 | 2.5 | 26 | Citations (PDF) |
| 104 | Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study | 16.1 | 121 | Citations (PDF) |
| 105 | Myocardial work and vascular dysfunction are partially improved at 12 months after
COVID
‐19 infection | 5.0 | 55 | Citations (PDF) |
| 106 | Future Developments in the Treatment of AL Amyloidosis | 0.4 | 6 | Citations (PDF) |
| 107 | Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals | 0.6 | 18 | Citations (PDF) |
| 108 | An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment | 1.4 | 7 | Citations (PDF) |
| 109 | Patients With Autoimmune Thyroiditis Present Similar Immunological Response to COVID-19 BNT162b2 mRNA Vaccine With Healthy Subjects, While Vaccination May Affect Thyroid Function: A Clinical Study | 2.8 | 19 | Citations (PDF) |
| 110 | Treatment Resistance Risk in Patients with Newly Diagnosed Multiple Myeloma Is Associated with Blood Hypercoagulability: The ROADMAP-MM Study | 0.4 | 2 | Citations (PDF) |
| 111 | Diabetes and COVID-19; A Bidirectional Interplay | 2.8 | 70 | Citations (PDF) |
| 112 | The COMPASS-COVID-19-ICU Study: Identification of Factors to Predict the Risk of Intubation and Mortality in Patients with Severe COVID-19 | 0.4 | 1 | Citations (PDF) |
| 113 | Oncological Patients With Endocrine Complications After Immunotherapy With Checkpoint Inhibitors Present Longer Progression-Free and Overall Survival | 1.7 | 22 | Citations (PDF) |
| 114 | Physical Exercise Restrains Cancer Progression through Muscle-Derived Factors | 2.7 | 31 | Citations (PDF) |
| 115 | Comparison of MRI Features of Fat Fraction and ADC for Early Treatment Response Assessment in Participants with Multiple Myeloma | 6.7 | 40 | Citations (PDF) |
| 116 | Characterizing Kinetics and Avidity of SARS-CoV-2 Antibody Responses in COVID-19 Greek Patients | 2.2 | 7 | Citations (PDF) |
| 117 | Plasma Metabolomic Alterations Induced by COVID-19 Vaccination Reveal Putative Biomarkers Reflecting the Immune Response | 3.3 | 33 | Citations (PDF) |
| 118 | “The emerging role of capivasertib in breast cancer” | 0.9 | 97 | Citations (PDF) |
| 119 | Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma | 0.8 | 8 | Citations (PDF) |
| 120 | Immunogenic Cell Death, DAMPs and Prothymosin α as a Putative Anticancer Immune Response Biomarker | 3.3 | 86 | Citations (PDF) |
| 121 | Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial | 7.5 | 45 | Citations (PDF) |
| 122 | Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma | 1.4 | 17 | Citations (PDF) |
| 123 | Reduced Antibodies and Innate Cytokine Changes in SARS-CoV-2 BNT162b2 mRNA Vaccinated Transplant Patients With Hematological Malignancies | 3.3 | 18 | Citations (PDF) |
| 124 | Newly Diagnosed Multiple Myeloma Patients with Skeletal-Related Events and Abnormal MRI Pattern Have Poor Survival Outcomes: A Prospective Study on 370 Patients | 1.8 | 11 | Citations (PDF) |
| 125 | SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint Inhibition | 2.7 | 9 | Citations (PDF) |
| 126 | Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study “REBUILD” | 2.7 | 21 | Citations (PDF) |
| 127 | Melflufen for the treatment of multiple myeloma | 1.9 | 7 | Citations (PDF) |
| 128 | Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls | 1.8 | 12 | Citations (PDF) |
| 129 | Chromosome 1q21 aberrations identify ultra high‐risk myeloma with prognostic and clinical implications | 5.2 | 30 | Citations (PDF) |
| 130 | Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes | 10.8 | 32 | Citations (PDF) |
| 131 | Third Dose of the BNT162b2 Vaccine Results in Sustained High Levels of Neutralizing Antibodies Against SARS-CoV-2 at 6 Months Following Vaccination in Healthy Individuals | 0.6 | 6 | Citations (PDF) |
| 132 | SARS‐CoV‐2 humoral responses following booster BNT162b2 vaccination in patients with B‐cell malignancies | 5.2 | 15 | Citations (PDF) |
| 133 | Distinct type I interferon responses between younger women and older men contribute to the variability of COVID-19 outcomes: Hypothesis generating insights from COVID-19 convalescent individuals | 2.0 | 7 | Citations (PDF) |
| 134 | Multi-Gene Mutation Profiling by Targeted Next-Generation Sequencing in Premenopausal Breast Cancer | 1.8 | 7 | Citations (PDF) |
| 135 | Single-cell multimodal analysis identifies common regulatory programs in synovial fibroblasts of rheumatoid arthritis patients and modeled TNF-driven arthritis | 5.9 | 64 | Citations (PDF) |
| 136 | Risk for Arterial Thromboembolic Events (ATEs) in Patients with Advanced Urinary Tract Cancer (aUTC) Treated with First-Line Chemotherapy: Single-Center, Observational Study | 2.0 | 4 | Citations (PDF) |
| 137 | COVID-19 mRNA vaccine-induced adverse effects: unwinding the unknowns | 6.4 | 6 | Citations (PDF) |
| 138 | Cardiopulmonary Exercise Physiology in AL Amyloidosis Patients with Cardiac Involvement and Its Association with Cardiac Imaging Parameters | 1.8 | 2 | Citations (PDF) |
| 139 | Assessment of Postvaccination Neutralizing Antibodies Response against SARS-CoV-2 in Cancer Patients under Treatment with Targeted Agents | 1.9 | 4 | Citations (PDF) |
| 140 | Subarachnoid hemorrhage in a postpartum mother: A rare manifestation of an uncommon disease | 0.4 | 3 | Citations (PDF) |
| 141 | COVID-19 BNT162b2 mRNA vaccine for patients with type 2 diabetes mellitus | 1.2 | 2 | Citations (PDF) |
| 142 | Managing Waldenström’s macroglobulinemia with BTK inhibitors | 3.7 | 44 | Citations (PDF) |
| 143 | An Untargeted Metabolomics Approach on Carfilzomib-Induced Nephrotoxicity | 3.2 | 5 | Citations (PDF) |
| 144 | Chasing Hippos: Implications of YAP1 and TAZ Expression in Pregnancy-associated Breast Cancer Tumorigenesis | 0.8 | 1 | Citations (PDF) |
| 145 | Diagnostics in Waldenström’s macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s Macroglobulinemia | 3.7 | 45 | Citations (PDF) |
| 146 | Low Spike Antibody Levels and Impaired BA.4/5 Neutralization in Patients with Multiple Myeloma or Waldenstrom’s Macroglobulinemia after BNT162b2 Booster Vaccination | 2.7 | 15 | Citations (PDF) |
| 147 | Approach to Contemporary Risk Assessment, Prevention and Management of Thrombotic Complications in Multiple Myeloma | 2.7 | 17 | Citations (PDF) |
| 148 | Germline and somatic variants in ovarian carcinoma: A next-generation sequencing (NGS) analysis | 1.7 | 29 | Citations (PDF) |
| 149 | The Combination of Panobinostat and Melphalan for the Treatment of Patients with Multiple Myeloma | 3.2 | 7 | Citations (PDF) |
| 150 | Trastuzumab Deruxtecan (DS-8201a): The Latest Research and Advances in Breast Cancer | 1.6 | 71 | Citations (PDF) |
| 151 | Next generation flow cytometry for MRD detection in patients with AL amyloidosis | 2.6 | 33 | Citations (PDF) |
| 152 | Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis | 2.6 | 32 | Citations (PDF) |
| 153 | Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myelomaBlood, 2021, 137, 1154-1165 | 3.6 | 77 | Citations (PDF) |
| 154 | Analytical methodologies for the detection of SARS-CoV-2 in wastewater: Protocols and future perspectives | 9.0 | 107 | Citations (PDF) |
| 155 | Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study | 16.1 | 66 | Citations (PDF) |
| 156 | Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies | 1.0 | 16 | Citations (PDF) |
| 157 | Daratumumab‐based therapy for patients with monoclonal gammopathy of renal significance | 1.7 | 35 | Citations (PDF) |
| 158 | Screening for Gaucher disease among patients with plasma cell dyscrasias | 1.0 | 3 | Citations (PDF) |
| 159 | COVID-19: time to flatten the infodemic curve | 2.2 | 31 | Citations (PDF) |
| 160 | Current and novel BTK inhibitors in Waldenström’s macroglobulinemia | 1.4 | 20 | Citations (PDF) |
| 161 | Clinical perspectives of BET inhibition in ovarian cancer | 3.1 | 44 | Citations (PDF) |
| 162 | Cardiac amyloidosis presenting with coronary artery embolization | 1.1 | 1 | Citations (PDF) |
| 163 | Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications | 8.1 | 235 | Citations (PDF) |
| 164 | Mutation-dependent treatment approaches for patients with complex multiple myeloma | 1.0 | 0 | Citations (PDF) |
| 165 | Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study | 3.7 | 29 | Citations (PDF) |
| 166 | Continuing Cancer Therapy through the Pandemic While Protecting Our Patients: Results of the Implementation of Preventive Strategies in a Referral Oncology Unit | 2.7 | 4 | Citations (PDF) |
| 167 | Vascular Inflammation and Cardiovascular Burden in Metastatic Breast Cancer Female Patients Receiving Hormonal Treatment and CDK 4/6 Inhibitors or Everolimus | 1.6 | 16 | Citations (PDF) |
| 168 | Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations | 1.7 | 165 | Citations (PDF) |
| 169 | Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study | 2.7 | 15 | Citations (PDF) |
| 170 | SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response | 1.9 | 14 | Citations (PDF) |
| 171 | Exercise-Induced Changes in Tumor Growth via Tumor Immunity | 1.4 | 27 | Citations (PDF) |
| 172 | Accurate SARS-CoV-2 seroprevalence surveys require robust multi-antigen assays | 2.7 | 37 | Citations (PDF) |
| 173 | Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group | 16.1 | 197 | Citations (PDF) |
| 174 | Recovery of Innate Immune Cells and Persisting Alterations in Adaptive Immunity in the Peripheral Blood of Convalescent Plasma Donors at Eight Months Post SARS-CoV-2 Infection | 2.7 | 20 | Citations (PDF) |
| 175 | Management of the Elderly Patients with High-Grade Serous Ovarian Cancer in the REAL-WORLD Setting | 2.0 | 15 | Citations (PDF) |
| 176 | The relationship between cardiac injury, inflammation and coagulation in predicting COVID-19 outcome | 2.7 | 11 | Citations (PDF) |
| 177 | Whole-Body Low-Dose CT in Multiple Myeloma: Diagnostic Value of Appendicular Medullary Patterns of Attenuation | 2.9 | 24 | Citations (PDF) |
| 178 | Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group | 16.1 | 244 | Citations (PDF) |
| 179 | Cardiovascular toxicity of breast cancer treatment: an update | 1.3 | 18 | Citations (PDF) |
| 180 | The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma | 1.9 | 22 | Citations (PDF) |
| 181 | Trastuzumab administration during pregnancy: an update | 2.1 | 38 | Citations (PDF) |
| 182 | Health‐related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial | 1.7 | 17 | Citations (PDF) |
| 183 | Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma | 15.4 | 15 | Citations (PDF) |
| 184 | A Phase II Study on the Use of Convalescent Plasma for the Treatment of Severe COVID-19- A Propensity Score-Matched Control Analysis | 2.7 | 13 | Citations (PDF) |
| 185 | Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine doseBlood, 2021, 137, 3674-3676 | 3.6 | 140 | Citations (PDF) |
| 186 | Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors | 15.4 | 35 | Citations (PDF) |
| 187 | Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients | 2.7 | 21 | Citations (PDF) |
| 188 | Germline mutations in a clinic-based series of pregnancy associated breast cancer patients | 2.1 | 18 | Citations (PDF) |
| 189 | Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma | 5.2 | 21 | Citations (PDF) |
| 190 | The COVID-19 Pandemic and the Need for an Integrated and Equitable Approach: An International Expert Consensus Paper | 2.3 | 29 | Citations (PDF) |
| 191 | Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP | 2.5 | 26 | Citations (PDF) |
| 192 | Management of Patients with Difficult-To-Treat Multiple Myeloma | 1.7 | 1 | Citations (PDF) |
| 193 | Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial | 46.9 | 343 | Citations (PDF) |
| 194 | Overweight/Obesity and Monoclonal Gammopathy of Undetermined Significance | 0.8 | 18 | Citations (PDF) |
| 195 | Real-World Treatment of Patients With Relapsed/Refractory Myeloma | 0.8 | 15 | Citations (PDF) |
| 196 | CDK4/6 Inhibitors and Arthralgia: A Single Institution Experience | 2.1 | 2 | Citations (PDF) |
| 197 | Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial | 16.1 | 309 | Citations (PDF) |
| 198 | A Molecular Signature of Circulating MicroRNA Can Predict Osteolytic Bone Disease in Multiple Myeloma | 2.7 | 17 | Citations (PDF) |
| 199 | Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review | 2.5 | 164 | Citations (PDF) |
| 200 | High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events | 1.9 | 26 | Citations (PDF) |
| 201 | Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine | 2.2 | 35 | Citations (PDF) |
| 202 | Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk | 5.2 | 33 | Citations (PDF) |
| 203 | Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis | 26.4 | 649 | Citations (PDF) |
| 204 | Antibody Response After Initial Vaccination for SARS-CoV-2 in Patients With Amyloidosis | 0.6 | 7 | Citations (PDF) |
| 205 | Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers | 3.3 | 42 | Citations (PDF) |
| 206 | SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors | 2.4 | 66 | Citations (PDF) |
| 207 | Association Of -308G/A, -238G/A TNF-α Polymorphisms with Multiple Myeloma Risk and Survival: A Systematic Review and Meta-Analysis | 0.8 | 3 | Citations (PDF) |
| 208 | Ibrutinib plus rituximab for the treatment of adult patients with Waldenström’s macroglobulinemia: a safety evaluation | 1.6 | 4 | Citations (PDF) |
| 209 | Aberrant Plasma Cell Contamination of Peripheral Blood Stem Cell Autografts, Assessed by Next-Generation Flow Cytometry, Is a Negative Predictor for Deep Response Post Autologous Transplantation in Multiple Myeloma; A Prospective Study in 199 Patients | 2.7 | 20 | Citations (PDF) |
| 210 | MicroRNAs as Potential Predictors of Response to CDK4/6 Inhibitor Treatment | 2.7 | 21 | Citations (PDF) |
| 211 | Paraneoplastic cerebellar degeneration in platinum-responsive endometrial cancer: A case report and review of literature | 0.4 | 3 | Citations (PDF) |
| 212 | Systemic IL-15, IFN-γ, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients | 4.4 | 228 | Citations (PDF) |
| 213 | Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study Group | 1.8 | 16 | Citations (PDF) |
| 214 | Novel Nested-Seq Approach for SARS-CoV-2 Real-Time Epidemiology and In-Depth Mutational Profiling in Wastewater | 3.2 | 17 | Citations (PDF) |
| 215 | Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients | 4.4 | 59 | Citations (PDF) |
| 216 | The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment | 4.1 | 118 | Citations (PDF) |
| 217 | Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study | 2.7 | 46 | Citations (PDF) |
| 218 | Isatuximab for Relapsed/Refractory Multiple Myeloma: Review of Key Subgroup Analyses from the Phase III ICARIA-MM Study | 1.7 | 16 | Citations (PDF) |
| 219 | Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study | 3.7 | 43 | Citations (PDF) |
| 220 | Association of
COVID
‐19 with impaired endothelial glycocalyx, vascular function and myocardial deformation 4 months after infection | 5.0 | 125 | Citations (PDF) |
| 221 | Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease | 2.6 | 21 | Citations (PDF) |
| 222 | Occupational Exposure and Multiple Myeloma Risk: An Updated Review of Meta-Analyses | 1.8 | 28 | Citations (PDF) |
| 223 | Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma | 2.2 | 6 | Citations (PDF) |
| 224 | Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study | 2.1 | 16 | Citations (PDF) |
| 225 | Patterns of pharmaceuticals use during the first wave of COVID-19 pandemic in Athens, Greece as revealed by wastewater-based epidemiology | 5.6 | 125 | Citations (PDF) |
| 226 | SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors | 0.9 | 20 | Citations (PDF) |
| 227 | Change in the chemical content of untreated wastewater of Athens, Greece under COVID-19 pandemic | 5.6 | 107 | Citations (PDF) |
| 228 | Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review | 2.7 | 16 | Citations (PDF) |
| 229 | Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection | 2.2 | 35 | Citations (PDF) |
| 230 | Obesity, metabolic syndrome, and cancer: pathophysiological and therapeutic associations | 1.8 | 126 | Citations (PDF) |
| 231 | Elucidating Carfilzomib’s Induced Cardiotoxicity in an In Vivo Model of Aging: Prophylactic Potential of Metformin | 3.2 | 18 | Citations (PDF) |
| 232 | Nocebo-Prone Behavior Associated with SARS-CoV-2 Vaccine Hesitancy in Healthcare Workers | 1.9 | 9 | Citations (PDF) |
| 233 | Metabolic Disorders in Multiple Myeloma | 3.2 | 35 | Citations (PDF) |
| 234 | Pembrolizumab in endometrial cancer: Where we stand now (Review) | 1.1 | 18 | Citations (PDF) |
| 235 | Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals | 1.9 | 26 | Citations (PDF) |
| 236 | Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors | 1.9 | 15 | Citations (PDF) |
| 237 | Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic Versus Clinical Infection | 3.3 | 13 | Citations (PDF) |
| 238 | Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective Study | 2.7 | 12 | Citations (PDF) |
| 239 | miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome | 4.1 | 19 | Citations (PDF) |
| 240 | ERCC1 19007 Polymorphism in Greek Patients with Advanced Urothelial Cancer Treated with Platinum-Based Chemotherapy: Effect of the Changing Treatment Paradigm: A Cohort Study by the Hellenic GU Cancer Group | 2.0 | 1 | Citations (PDF) |
| 241 | BRCA1/2 Mutation Types Do Not Affect Prognosis in Ovarian Cancer Patients | 2.0 | 5 | Citations (PDF) |
| 242 | Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis | 1.4 | 7 | Citations (PDF) |
| 243 | What Has Changed in the Management of Uterine Serous Carcinomas? Two Decades of Experience | 2.0 | 1 | Citations (PDF) |
| 244 | Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection | 3.3 | 35 | Citations (PDF) |
| 245 | tRNA Derivatives in Multiple Myeloma: Investigation of the Potential Value of a tRNA-Derived Molecular Signature | 2.5 | 10 | Citations (PDF) |
| 246 | Daratumumab for Immunoglobulin Light Chain Amyloidosis | 0.2 | 0 | Citations (PDF) |
| 247 | A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma | 3.2 | 23 | Citations (PDF) |
| 248 | The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison | 1.0 | 13 | Citations (PDF) |
| 249 | A matching-adjusted indirect treatment comparison (MAIC) of daratumumab–bortezomib–melphalan–prednisone (D-VMP) versus lenalidomide–dexamethasone continuous (Rd continuous), lenalidomide–dexamethasone 18 months (Rd 18), and melphalan–prednisone–thalidomide (MPT) | 1.0 | 5 | Citations (PDF) |
| 250 | Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials | 1.0 | 7 | Citations (PDF) |
| 251 | Multiple myeloma: Role of autologous transplantation | 6.0 | 60 | Citations (PDF) |
| 252 | Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design | 1.7 | 67 | Citations (PDF) |
| 253 | Quality of life is maintained with ixazomib maintenance in post‐transplant newly diagnosed multiple myeloma: The TOURMALINE‐MM3 trial | 1.5 | 14 | Citations (PDF) |
| 254 | Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia | 7.5 | 140 | Citations (PDF) |
| 255 | Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report | 1.9 | 31 | Citations (PDF) |
| 256 | The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma | 4.1 | 25 | Citations (PDF) |
| 257 | Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity | 2.7 | 31 | Citations (PDF) |
| 258 | Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction | 1.8 | 1 | Citations (PDF) |
| 259 | International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM) | 4.1 | 274 | Citations (PDF) |
| 260 | The Genomic Profile of Pregnancy-Associated Breast Cancer: A Systematic Review | 1.7 | 30 | Citations (PDF) |
| 261 | Cardiac arrest and drug-related cardiac toxicity in the Covid-19 era. Epidemiology, pathophysiology and management | 2.0 | 8 | Citations (PDF) |
| 262 | Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study | 46.9 | 401 | Citations (PDF) |
| 263 | Clinical Perspectives of ERCC1 in Bladder Cancer | 3.2 | 13 | Citations (PDF) |
| 264 | Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma | 3.7 | 31 | Citations (PDF) |
| 265 | Update in COVID-19 in the intensive care unit from the 2020 HELLENIC Athens International symposium | 1.5 | 28 | Citations (PDF) |
| 266 | Chemotherapy resumption in ovarian cancer patient diagnosed with COVID-19 | 0.4 | 8 | Citations (PDF) |
| 267 | Ex Vivo Models Simulating the Bone Marrow Environment and Predicting Response to Therapy in Multiple Myeloma | 2.7 | 20 | Citations (PDF) |
| 268 | Organ-specific manifestations of COVID-19 infection | 2.2 | 435 | Citations (PDF) |
| 269 | Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis | 12.4 | 150 | Citations (PDF) |
| 270 | Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib | 3.2 | 25 | Citations (PDF) |
| 271 | Renal pathology in patients with monoclonal gammopathy or multiple myeloma: monoclonal immunoglobulins are not always the cause | 1.0 | 5 | Citations (PDF) |
| 272 | A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN studyBlood, 2020, 136, 2038-2050 | 3.6 | 451 | Citations (PDF) |
| 273 | Derivation and Validation of a Predictive Score for Disease Worsening in Patients with COVID-19 | 2.3 | 43 | Citations (PDF) |
| 274 | Emerging drugs for the treatment of Waldenström macroglobulinemia | 2.0 | 3 | Citations (PDF) |
| 275 | Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine | 2.3 | 149 | Citations (PDF) |
| 276 | Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study | 4.1 | 137 | Citations (PDF) |
| 277 | The emerging role of BET inhibitors in breast cancer | 0.9 | 48 | Citations (PDF) |
| 278 | Anti–SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study | 2.7 | 40 | Citations (PDF) |
| 279 | Long-Term Neurodevelopmental Outcome of Children after in Utero Exposure to Chemotherapy | 2.7 | 19 | Citations (PDF) |
| 280 | A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma | 3.7 | 408 | Citations (PDF) |
| 281 | Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX | 4.1 | 16 | Citations (PDF) |
| 282 | Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients | 4.1 | 36 | Citations (PDF) |
| 283 | Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma | 2.7 | 32 | Citations (PDF) |
| 284 | Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial | 46.9 | 316 | Citations (PDF) |
| 285 | Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID‐19 pandemic | 1.7 | 21 | Citations (PDF) |
| 286 | Phase 2 study of cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanes—a Hellenic Cooperative Oncology Group (HeCOG) Trial | 4.1 | 14 | Citations (PDF) |
| 287 | Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: A metanalysis with meta-regression | 6.0 | 51 | Citations (PDF) |
| 288 | Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period | 1.0 | 16 | Citations (PDF) |
| 289 | Primary plasma cell leukemia presenting as secondary pulmonary alveolar proteinosis | 1.0 | 0 | Citations (PDF) |
| 290 | Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis | 4.1 | 17 | Citations (PDF) |
| 291 | Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd | 1.5 | 44 | Citations (PDF) |
| 292 | Lymphocytic infiltration and Chemotherapy Response Score as prognostic markers in ovarian cancer patients treated with Neoadjuvant chemotherapy | 2.3 | 9 | Citations (PDF) |
| 293 | Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma | 4.1 | 21 | Citations (PDF) |
| 294 | Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma | 1.0 | 6 | Citations (PDF) |
| 295 | A Noninterventional, Observational, European Post-Authorization Safety Study of Patients With Relapsed/Refractory Multiple Myeloma Treated With Lenalidomide | 0.8 | 2 | Citations (PDF) |
| 296 | The current role of BTK inhibitors in the treatment of Waldenstrom’s Macroglobulinemia | 1.5 | 5 | Citations (PDF) |
| 297 | Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome | 0.6 | 27 | Citations (PDF) |
| 298 | The Emerging Role of Convalescent Plasma in the Treatment of COVID‐19 | 0.6 | 45 | Citations (PDF) |
| 299 | Real‐world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco‐Israeli collaborative myeloma working group | 5.2 | 17 | Citations (PDF) |
| 300 | Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes | 1.8 | 37 | Citations (PDF) |
| 301 | Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma | 4.1 | 108 | Citations (PDF) |
| 302 | Once‐weekly (70 mg/m2) vs twice‐weekly (56 mg/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION‐1 trials | 2.0 | 19 | Citations (PDF) |
| 303 | Involvement of small nerve fibres and autonomic nervous system in AL amyloidosis: comprehensive characteristics and clinical implications | 2.6 | 21 | Citations (PDF) |
| 304 | Early Relapse After Autologous Transplant Is Associated With Very Poor Survival and Identifies an Ultra-High-Risk Group of Patients With Myeloma | 0.8 | 46 | Citations (PDF) |
| 305 | Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study | 7.5 | 361 | Citations (PDF) |
| 306 | Hematological findings and complications of COVID‐19 | 5.2 | 1,569 | Citations (PDF) |
| 307 | Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma | 1.0 | 41 | Citations (PDF) |
| 308 | Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma | 1.0 | 12 | Citations (PDF) |
| 309 | Cost-effectiveness of once weekly carfilzomib 70 mg/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States | 1.5 | 5 | Citations (PDF) |
| 310 | Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma | 3.7 | 19 | Citations (PDF) |
| 311 | Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myeloma | 1.0 | 32 | Citations (PDF) |
| 312 | Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents | 4.1 | 26 | Citations (PDF) |
| 313 | Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma | 3.7 | 73 | Citations (PDF) |
| 314 | Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III Studies | 0.8 | 8 | Citations (PDF) |
| 315 | Emerging treatment strategies for COVID-19 infection | 2.2 | 292 | Citations (PDF) |
| 316 | Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse | 3.7 | 58 | Citations (PDF) |
| 317 | Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study | 3.7 | 211 | Citations (PDF) |
| 318 | Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis | 3.7 | 63 | Citations (PDF) |
| 319 | Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN) | 3.7 | 121 | Citations (PDF) |
| 320 | Significant reduction in the visits to the emergency room department during the COVID-19 pandemic in a tertiary hospital in Greece | 1.0 | 22 | Citations (PDF) |
| 321 | The Prognostic Role of Protein Expression in Pregnancy Associated Breast Cancer: A Literature Review | 0.1 | 1 | Citations (PDF) |
| 322 | Oncology during the COVID‑19 pandemic: challenges, dilemmas and the psychosocial impact on cancer patients (Review) | 1.1 | 148 | Citations (PDF) |
| 323 | Clinical biomarkers directing the management of patients with colon and lung cancer (beyond oncogene-addicted NSCLC) | 0.0 | 6 | Citations (PDF) |
| 324 | Taxanes during pregnancy in cervical cancer: A systematic review and pooled analysis | 6.0 | 21 | Citations (PDF) |
| 325 | Reactive Vasodilation Predicts Mortality in Primary Systemic Light-Chain Amyloidosis | 8.6 | 36 | Citations (PDF) |
| 326 | Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials | 0.9 | 14 | Citations (PDF) |
| 327 | Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma | 26.4 | 630 | Citations (PDF) |
| 328 | Monoclonal antibodies against RANKL and sclerostin for myeloma-related bone disease: can they change the standard of care? | 1.5 | 14 | Citations (PDF) |
| 329 | <p>Evaluating ibrutinib in the treatment of symptomatic Waldenstrom’s macroglobulinemia</p> | 1.9 | 13 | Citations (PDF) |
| 330 | Modelization of Blood-Borne Hypercoagulability in Myeloma: A Tissue-Factor-Bearing Microparticle-Driven Process | 0.8 | 9 | Citations (PDF) |
| 331 | Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study | 46.9 | 595 | Citations (PDF) |
| 332 | Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma | 1.5 | 8 | Citations (PDF) |
| 333 | Non‐lethal proteasome inhibition activates pro‐tumorigenic pathways in multiple myeloma cells | 2.4 | 6 | Citations (PDF) |
| 334 | How I treat Waldenström macroglobulinemiaBlood, 2019, 134, 2022-2035 | 3.6 | 96 | Citations (PDF) |
| 335 | Hereditary systemic amyloidosis caused by K19T apolipoprotein C-II variant | 2.6 | 6 | Citations (PDF) |
| 336 | A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options | 1.8 | 14 | Citations (PDF) |
| 337 | Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma | 1.0 | 56 | Citations (PDF) |
| 338 | Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups | 0.8 | 63 | Citations (PDF) |
| 339 | A revised international prognostic score system for Waldenström’s macroglobulinemia | 3.7 | 106 | Citations (PDF) |
| 340 | Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial | 16.1 | 355 | Citations (PDF) |
| 341 | A 50-Year-Long Study of Waldenström Macroglobulinemia | 1.9 | 2 | Citations (PDF) |
| 342 | Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m2 vs. twice-weekly 27 mg/m2 carfilzomib (randomized A.R.R.O.W. study) | 3.7 | 26 | Citations (PDF) |
| 343 | Toll-Like Receptor 4 Activation Promotes Multiple Myeloma Cell Growth and Survival Via Suppression of The Endoplasmic Reticulum Stress Factor Chop | 2.7 | 32 | Citations (PDF) |
| 344 | Meat, fish, dairy products and risk of hematological malignancies in adults – a systematic review and meta-analysis of prospective studies | 1.0 | 21 | Citations (PDF) |
| 345 | Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome | 1.0 | 10 | Citations (PDF) |
| 346 | Updates on thrombotic events associated with multiple myeloma | 1.5 | 14 | Citations (PDF) |
| 347 | Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies | 1.5 | 12 | Citations (PDF) |
| 348 | Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma | 4.1 | 37 | Citations (PDF) |
| 349 | Systemic therapy in cervical cancer: 30 years in review | 3.5 | 189 | Citations (PDF) |
| 350 | The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG) | 4.1 | 99 | Citations (PDF) |
| 351 | Bone marrow biopsy in low‐risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group | 5.2 | 13 | Citations (PDF) |
| 352 | Insights on Multiple Myeloma Treatment Strategies | 0.6 | 39 | Citations (PDF) |
| 353 | Myeloma bone disease: from biology findings to treatment approachesBlood, 2019, 133, 1534-1539 | 3.6 | 132 | Citations (PDF) |
| 354 | Olaratumab administered in two cases of phyllodes tumour of the breast: end of the beginning? | 3.2 | 10 | Citations (PDF) |
| 355 | Optimizing Immunomodulatory Drug With Proteasome Inhibitor Combinations in Newly Diagnosed Multiple Myeloma | 1.0 | 15 | Citations (PDF) |
| 356 | Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy | 0.6 | 31 | Citations (PDF) |
| 357 | Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone | 3.7 | 21 | Citations (PDF) |
| 358 | Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone | 3.7 | 54 | Citations (PDF) |
| 359 | Antitumor Reactive T-Cell Responses Are Enhanced In Vivo by DAMP Prothymosin Alpha and Its C-Terminal Decapeptide | 2.7 | 12 | Citations (PDF) |
| 360 | Treatment of Bing–Neel syndrome with first line sequential chemoimmunotherapy | 1.0 | 10 | Citations (PDF) |
| 361 | Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates | 5.2 | 27 | Citations (PDF) |
| 362 | Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVORBlood, 2019, 133, 147-155 | 3.6 | 39 | Citations (PDF) |
| 363 | Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metforminBlood, 2019, 133, 710-723 | 3.6 | 118 | Citations (PDF) |
| 364 | All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma | 2.8 | 30 | Citations (PDF) |
| 365 | Phase 2 study of all‐oral ixazomib, cyclophosphamide and low‐dose dexamethasone for relapsed/refractory multiple myeloma | 1.7 | 21 | Citations (PDF) |
| 366 | Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma | 2.8 | 13 | Citations (PDF) |
| 367 | Anthropometric characteristics, physical activity and risk of hematological malignancies: A systematic review and meta‐analysis of cohort studies | 2.8 | 56 | Citations (PDF) |
| 368 | The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study | 1.6 | 5 | Citations (PDF) |
| 369 | Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial | 46.9 | 229 | Citations (PDF) |
| 370 | A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial | 3.7 | 217 | Citations (PDF) |
| 371 | Alcohol consumption and risk of hematological malignancies: A meta‐analysis of prospective studies | 2.8 | 46 | Citations (PDF) |
| 372 | How We Manage Patients with Plasmacytomas | 2.2 | 12 | Citations (PDF) |
| 373 | Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosisBlood, 2018, 131, 1568-1575 | 3.6 | 59 | Citations (PDF) |
| 374 | Pathogenesis of bone disease in multiple myeloma: from bench to bedside | 4.1 | 323 | Citations (PDF) |
| 375 | Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study | 4.1 | 34 | Citations (PDF) |
| 376 | Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network | 3.7 | 90 | Citations (PDF) |
| 377 | Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia | 0.8 | 7 | Citations (PDF) |
| 378 | Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group | 4.1 | 50 | Citations (PDF) |
| 379 | Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma | 26.4 | 931 | Citations (PDF) |
| 380 | Rare manifestations of extramedullary myeloma: testicular plasmacytomas | 1.0 | 6 | Citations (PDF) |
| 381 | Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myelomaBlood, 2018, 131, 301-310 | 3.6 | 252 | Citations (PDF) |
| 382 | The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agentsBlood, 2018, 131, 464-467 | 3.6 | 59 | Citations (PDF) |
| 383 | Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases | 1.0 | 5 | Citations (PDF) |
| 384 | SP159OUTCOME OF PATIENTS WITH FIBRILARY GLOMERULONEPHRITIS : A SINGLE CENTER EXPERIENCE | 0.7 | 0 | Citations (PDF) |
| 385 | Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | 12.4 | 266 | Citations (PDF) |
| 386 | Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis | 2.6 | 31 | Citations (PDF) |
| 387 | Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting | 4.1 | 221 | Citations (PDF) |
| 388 | Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study | 4.1 | 33 | Citations (PDF) |
| 389 | Ibrutinib and Rituximab in Waldenström’s Macroglobulinemia | 26.4 | 7 | Citations (PDF) |
| 390 | Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma | 26.4 | 509 | Citations (PDF) |
| 391 | Cardio-oncology: A Focus on Cardiotoxicity | 1.8 | 100 | Citations (PDF) |
| 392 | Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group | 4.1 | 86 | Citations (PDF) |
| 393 | Pharmacokinetics and Exposure–Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma | 2.7 | 30 | Citations (PDF) |
| 394 | Prognostic factors for multiple myeloma in the era of novel therapies | 1.5 | 30 | Citations (PDF) |
| 395 | Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4‐year follow‐up and analysis of relative progression‐free survival from the randomized ELOQUENT‐2 trial | 2.7 | 129 | Citations (PDF) |
| 396 | A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial | 3.7 | 73 | Citations (PDF) |
| 397 | Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis | 4.1 | 45 | Citations (PDF) |
| 398 | Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study | 16.1 | 201 | Citations (PDF) |
| 399 | Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia | 26.4 | 345 | Citations (PDF) |
| 400 | Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review | 7.5 | 50 | Citations (PDF) |
| 401 | Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study | 0.8 | 73 | Citations (PDF) |
| 402 | Proteasome Inhibitors in Waldenström Macroglobulinemia | 1.5 | 11 | Citations (PDF) |
| 403 | European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias | 3.7 | 94 | Citations (PDF) |
| 404 | Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies | 3.7 | 48 | Citations (PDF) |
| 405 | Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study | 15.4 | 41 | Citations (PDF) |
| 406 | Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma | 4.1 | 36 | Citations (PDF) |
| 407 | Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN) | 3.7 | 105 | Citations (PDF) |
| 408 | Emerging treatment approaches for myeloma-related bone disease | 1.5 | 14 | Citations (PDF) |
| 409 | Bevacizumab increases the incidence of cardiovascular events in patients with metastatic breast or colorectal cancer | 1.0 | 18 | Citations (PDF) |
| 410 | Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study | 1.7 | 62 | Citations (PDF) |
| 411 | Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study | 1.7 | 26 | Citations (PDF) |
| 412 | Diagnostic work-up and specific causes of acute kidney injury | 3.5 | 71 | Citations (PDF) |
| 413 | Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low‐dose dexamethasone: A pooled analysis | 1.5 | 24 | Citations (PDF) |
| 414 | Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation | 2.5 | 71 | Citations (PDF) |
| 415 | Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy | 5.2 | 71 | Citations (PDF) |
| 416 | Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup | 1.0 | 22 | Citations (PDF) |
| 417 | Population Pharmacokinetics and Exposure–Response Relationship of Carfilzomib in Patients With Multiple Myeloma | 1.3 | 12 | Citations (PDF) |
| 418 | Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial | 16.1 | 235 | Citations (PDF) |
| 419 | Current treatment options and investigational drugs for Waldenstrom’s Macroglobulinemia | 2.4 | 12 | Citations (PDF) |
| 420 | Gefitinib: an “orphan” drug for non-small cell lung cancer | 2.0 | 2 | Citations (PDF) |
| 421 | Daratumumab combinations: what can we learn?Blood, 2017, 130, 957-958 | 3.6 | 3 | Citations (PDF) |
| 422 | Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial | 16.1 | 387 | Citations (PDF) |
| 423 | Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT‐2 follow‐up and post‐hoc analyses on progression‐free survival and tumour growth | 1.7 | 131 | Citations (PDF) |
| 424 | Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies | 1.5 | 46 | Citations (PDF) |
| 425 | Dynamic contrast-enhanced magnetic resonance imaging parameters correlate with advanced revised-ISS and angiopoietin-1/angiopoietin-2 ratio in patients with multiple myeloma | 1.0 | 11 | Citations (PDF) |
| 426 | An overview of the role of carfilzomib in the treatment of multiple myeloma | 1.9 | 29 | Citations (PDF) |
| 427 | Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial | 1.7 | 21 | Citations (PDF) |
| 428 | Quantitative Diffusion-weighted Imaging of the Bone Marrow: An Adjunct Tool for the Diagnosis of a Diffuse MR Imaging Pattern in Patients with Multiple Myeloma | 6.7 | 96 | Citations (PDF) |
| 429 | Serum free immunoglobulin light chain fingerprint identifies a subset of newly diagnosed multiple myeloma patients with worse outcome | 1.6 | 7 | Citations (PDF) |
| 430 | Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events | 2.7 | 17 | Citations (PDF) |
| 431 | Cardiac and renal complications of carfilzomib in patients with multiple myeloma | 3.7 | 103 | Citations (PDF) |
| 432 | Disease control should be the goal of therapy for WM patients | 3.7 | 5 | Citations (PDF) |
| 433 | The Role of Imaging in the Treatment of Patients With Multiple Myeloma in 2016 | 4.5 | 50 | Citations (PDF) |
| 434 | Recent advances in the management of AL Amyloidosis | 1.7 | 97 | Citations (PDF) |
| 435 | Bortezomib‐based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis | 5.2 | 87 | Citations (PDF) |
| 436 | Proteasome inhibitor associated thrombotic microangiopathy | 5.2 | 111 | Citations (PDF) |
| 437 | Oxaliplatin-Induced Neuropathy: A Long-Term Clinical and Neurophysiologic Follow-Up Study | 1.1 | 50 | Citations (PDF) |
| 438 | A review of the venous thrombotic issues associated with multiple myeloma | 1.5 | 24 | Citations (PDF) |
| 439 | Emerging antibodies for the treatment of multiple myeloma | 2.0 | 26 | Citations (PDF) |
| 440 | Cytogenetics and Survival of Multiple Myeloma: Isolated and Combined Effects | 0.8 | 19 | Citations (PDF) |
| 441 | Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma | 8.5 | 37 | Citations (PDF) |
| 442 | DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7Blood, 2016, 128, 1214-1225 | 3.6 | 36 | Citations (PDF) |
| 443 | Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myelomaBlood, 2016, 128, 497-503 | 3.6 | 161 | Citations (PDF) |
| 444 | Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosisBlood, 2016, 128, 405-409 | 3.6 | 45 | Citations (PDF) |
| 445 | Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myelomaBlood, 2016, 128, 1174-1180 | 3.6 | 121 | Citations (PDF) |
| 446 | Treatment recommendations from the Eighth International Workshop on Waldenström’s MacroglobulinemiaBlood, 2016, 128, 1321-1328 | 3.6 | 179 | Citations (PDF) |
| 447 | Current therapy guidelines for Waldenstrom's macroglobulinaemia | 1.6 | 5 | Citations (PDF) |
| 448 | Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma | 26.4 | 1,397 | Citations (PDF) |
| 449 | Outcome of patients with nonmetastatic muscle‐invasive bladder cancer not undergoing cystectomy after treatment with noncisplatin‐based chemotherapy and/or radiotherapy: a retrospective analysis | 2.0 | 7 | Citations (PDF) |
| 450 | TLR4/TIRAP polymorphisms are associated with progression and survival of patients with symptomatic myeloma | 1.7 | 13 | Citations (PDF) |
| 451 | Current treatments for renal failure due to multiple myeloma | 1.9 | 33 | Citations (PDF) |
| 452 | International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma | 16.1 | 2,824 | Citations (PDF) |
| 453 | Managing renal complications in multiple myeloma | 1.5 | 22 | Citations (PDF) |
| 454 | Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia | 1.7 | 72 | Citations (PDF) |
| 455 | Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial | 7.5 | 146 | Citations (PDF) |
| 456 | Carfilzomib for treating myeloma | 2.0 | 2 | Citations (PDF) |
| 457 | Utilization of Systemic Chemotherapy in Advanced Urothelial Cancer: A Retrospective Collaborative Study by the Hellenic Genitourinary Cancer Group (HGUCG) | 1.5 | 8 | Citations (PDF) |
| 458 | Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study | 16.1 | 822 | Citations (PDF) |
| 459 | VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma | 0.8 | 28 | Citations (PDF) |
| 460 | The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective | 2.5 | 32 | Citations (PDF) |
| 461 | Primary failure of bortezomib in newly diagnosed multiple myeloma – understanding the magnitude, predictors, and significance | 1.0 | 14 | Citations (PDF) |
| 462 | Neutrophil Gelatinase–Associated Lipocalin and Cystatin C Are Sensitive Markers of Renal Injury in Patients With Multiple Myeloma | 0.8 | 17 | Citations (PDF) |
| 463 | Expression of α5-integrin, α7-integrin, Ε-cadherin, and N-cadherin in localized prostate cancer | 0.8 | 26 | Citations (PDF) |
| 464 | The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies | 6.0 | 65 | Citations (PDF) |
| 465 | Final Analysis of Overall Survival from the First TrialBlood, 2016, 128, 241-241 | 3.6 | 11 | Citations (PDF) |
| 466 | Bortezomib, Dexamethasone and Rituximab in Newly Diagnosed Patients with WaldenströM's Macroglobulinemia: Final Analysis of a Phase 2 Study after a Minimum Follow up of 6 YearsBlood, 2016, 128, 2957-2957 | 3.6 | 2 | Citations (PDF) |
| 467 | Health Related Quality of Life Results from the Open-Label, Randomized, Phase III Endeavor Trial Evaluating Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple MyelomaBlood, 2016, 128, 3309-3309 | 3.6 | 8 | Citations (PDF) |
| 468 | Pomalidomide with Low Dose Dexamethasone Is Effective Irrespective of Primary or Secondary Resistance to Lenalidomide but the IMiD-Free Interval Is ImportantBlood, 2016, 128, 3310-3310 | 3.6 | 1 | Citations (PDF) |
| 469 | Population Pharmacokinetic and Exposure-Response Analyses for Daratumumab in Combination Therapies for Patients with Multiple Myeloma Who Have Received 1 or More Prior Lines of TherapyBlood, 2016, 128, 3340-3340 | 3.6 | 1 | Citations (PDF) |
| 470 | Findings of Whole Body Computed Tomography Compared to Conventional Skeletal Survey in Patients with Monoclonal Plasma Cell Disorders - a Study of the International Myeloma Working GroupBlood, 2016, 128, 4468-4468 | 3.6 | 13 | Citations (PDF) |
| 471 | A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL AmyloidosisBlood, 2016, 128, 646-646 | 3.6 | 40 | Citations (PDF) |
| 472 | Intensification Therapy with Bortezomib-Melphalan-Prednisone Versus Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial)Blood, 2016, 128, 673-673 | 3.6 | 31 | Citations (PDF) |
| 473 | The Development of an Angiogenic Protein “Signature” in Ovarian Cancer Ascites as a Tool for Biologic and Prognostic Profiling | 1.5 | 26 | Citations (PDF) |
| 474 | The Role of Imaging in the Treatment of Patients With Multiple Myeloma in 2016 | 4.5 | 32 | Citations (PDF) |
| 475 | Glomerular expression of matrix metalloproteinases in AL-amyloidosis and association with renal function at the time of kidney biopsy | 0.4 | 9 | Citations (PDF) |
| 476 | Lenalidomide, Adriamycin, and Dexamethasone (RAD) As Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Eligible for Autologous Transplantation (ASCT): A Phase 2 Study from the Greek Myeloma Study GroupBlood, 2016, 128, 4488-4488 | 3.6 | 0 | Citations (PDF) |
| 477 | Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG StudyBlood, 2016, 128, 4414-4414 | 3.6 | 0 | Citations (PDF) |
| 478 | European Post-Approval Safety Study (PASS) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety, Including SPM, in a Large Cohort of Patients Treated with Lenalidomide, Thalidomide, and BortezomibBlood, 2016, 128, 3331-3331 | 3.6 | 0 | Citations (PDF) |
| 479 | Indirubins: A Potential Therapeutic Target in Multiple MyelomaBlood, 2016, 128, 3259-3259 | 3.6 | 0 | Citations (PDF) |
| 480 | Real-World Data on Clinical Characteristics, Prognosis and Outcome of Primary Plasma Cell Leukemia: A Study of the Greek Myeloma Study Group in the Era of Novel AgentsBlood, 2016, 128, 4490-4490 | 3.6 | 0 | Citations (PDF) |
| 481 | Safety Results of a Phase 2 Multicenter, Open-Label Study of Pomalidomide (CC-4047) Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) and Renal ImpairmentBlood, 2016, 128, 3311-3311 | 3.6 | 0 | Citations (PDF) |
| 482 | Addition of Cyclophosphamide and Higher Doses of Dexamethasone Do Not Improve Outcomes of Patients with AL Amyloidosis Treated with BortezomibBlood, 2016, 128, 4500-4500 | 3.6 | 0 | Citations (PDF) |
| 483 | Chromatin Histone Modifying and DNA Repair Inhibition Enhances the Anti-Myeloma Activity of MelphalanBlood, 2016, 128, 4437-4437 | 3.6 | 0 | Citations (PDF) |
| 484 | Long‐term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies | 5.2 | 57 | Citations (PDF) |
| 485 | Treatment options for relapsed and refractory multiple myelomaBlood, 2015, 125, 3085-3099 | 3.6 | 154 | Citations (PDF) |
| 486 | Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group reportBlood, 2015, 125, 2068-2074 | 3.6 | 737 | Citations (PDF) |
| 487 | Aberrant DNA Damage Response Pathways May Predict the Outcome of Platinum Chemotherapy in Ovarian Cancer | 1.5 | 39 | Citations (PDF) |
| 488 | Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma | 26.4 | 1,278 | Citations (PDF) |
| 489 | Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial | 0.8 | 42 | Citations (PDF) |
| 490 | Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib‐melphalan‐prednisone in the phase III VISTA study | 5.2 | 63 | Citations (PDF) |
| 491 | Alcohol intake, alcoholic beverage type and multiple myeloma risk: a meta-analysis of 26 observational studies | 1.0 | 16 | Citations (PDF) |
| 492 | Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement | 12.4 | 381 | Citations (PDF) |
| 493 | Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents | 1.0 | 21 | Citations (PDF) |
| 494 | Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience | 1.0 | 53 | Citations (PDF) |
| 495 | Clinical characteristics of patients with relapsed multiple myeloma | 6.0 | 37 | Citations (PDF) |
| 496 | Risk Factors for Multiple Myeloma: A Systematic Review of Meta-Analyses | 0.8 | 73 | Citations (PDF) |
| 497 | Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | 26.4 | 1,294 | Citations (PDF) |
| 498 | A phase 2, randomized, double‐blind, placebo‐controlled study of siltuximab (anti‐IL‐6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma | 5.2 | 124 | Citations (PDF) |
| 499 | Two cycles of adjuvant carboplatin in stage I seminoma: 8-year experience by the Hellenic Cooperative Oncology Group (HECOG) | 1.7 | 6 | Citations (PDF) |
| 500 | Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Results of the Phase 3 Study Endeavor (NCT01568866) According to Age SubgroupBlood, 2015, 126, 1844-1844 | 3.6 | 5 | Citations (PDF) |
| 501 | Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT02046070) | 3.6 | 16 | Citations (PDF) |
| 502 | Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up | 3.6 | 22 | Citations (PDF) |
| 503 | Efficacy and Safety of Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Endeavor (NCT01568866) | 3.6 | 8 | Citations (PDF) |
| 504 | Analysis of Pomalidomide Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with Vs without Moderate Renal ImpairmentBlood, 2015, 126, 3031-3031 | 3.6 | 3 | Citations (PDF) |
| 505 | The State of Chromatin Condensation, the Expression of Genes Involved in DNA Damage Response and the DNA Repair Capacity Affect the Drug Sensitivity of PBMCs of Myeloma Patients Treated with MelphalanBlood, 2015, 126, 3628-3628 | 3.6 | 2 | Citations (PDF) |
| 506 | Safety of Treatment (Tx) with Pomalidomide (POM) and Low-Dose Dexamethasone (LoDEX) in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI), Including Those on DialysisBlood, 2015, 126, 374-374 | 3.6 | 6 | Citations (PDF) |
| 507 | Diffusion-Weighted Imaging Improves Accuracy in the Diagnosis of MRI Patterns of Marrow Involvement in Newly Diagnosed Myeloma: Results of a Prospective Study in 99 PatientsBlood, 2015, 126, 4178-4178 | 3.6 | 12 | Citations (PDF) |
| 508 | Outcomes after Initial Relapse of Multiple Myeloma: An International Myeloma Working Group StudyBlood, 2015, 126, 4201-4201 | 3.6 | 4 | Citations (PDF) |
| 509 | An Updated Analysis of the Stratus Trial (MM-010): Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM + LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)Blood, 2015, 126, 4225-4225 | 3.6 | 3 | Citations (PDF) |
| 510 | A Frailty Scale Predicts Outcomes of Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone on the First TrialBlood, 2015, 126, 4239-4239 | 3.6 | 13 | Citations (PDF) |
| 511 | Serial Echocardiographic Assessment of Patients (Pts) with Relapsed Multiple Myeloma (RMM) Receiving Carfilzomib and Dexamethasone (Kd) Vs Bortezomib and Dexamethasone (Vd): A Substudy of the Phase 3 Endeavor Trial (NCT01568866)Blood, 2015, 126, 4250-4250 | 3.6 | 30 | Citations (PDF) |
| 512 | Impact of Cytogenetics on Outcomes of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone in the First (MM-020) TrialBlood, 2015, 126, 730-730 | 3.6 | 15 | Citations (PDF) |
| 513 | Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Aspire (NCT01080391)Blood, 2015, 126, 731-731 | 3.6 | 8 | Citations (PDF) |
| 514 | Global Myeloma Research Clusters, Output, and Citations: A Bibliometric Mapping and Clustering Analysis | 1.5 | 10 | Citations (PDF) |
| 515 | Pomalidomide – An Appraisal of Its Clinical Development and Role in the Treatment of Relapsed/Refractory Multiple Myeloma | 0.1 | 0 | Citations (PDF) |
| 516 | The Simultaneous Accumulation of the Extremely Cytotoxic Interstrand Cross-Links and Double-Strand Breaks Contributes to the Successful Anti-Myeloma Therapy; The Effect of DNA Repair InhibitorsBlood, 2015, 126, 4177-4177 | 3.6 | 0 | Citations (PDF) |
| 517 | Analysis of Patient (Pt) Outcomes By Prior Treatment and Depth of Response in Stratus (MM-010), a Phase 3b Study of Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)Blood, 2015, 126, 1834-1834 | 3.6 | 0 | Citations (PDF) |
| 518 | Bortezomib-Based Triplets Are Associated with a High Probability of Dialysis Independence and Rapid Renal Recovery in Newly Diagnosed Myeloma Patients with Severe Renal Failure or Those Requiring DialysisBlood, 2015, 126, 1832-1832 | 3.6 | 0 | Citations (PDF) |
| 519 | Analysis of Molecular-Cellular Responses to Proteasome Inhibitors in Multiple Myeloma Patients; A Translational Approach of Proteasome Inhibitors In Vivo Effects from the Drosophila Experimental Model to HumansBlood, 2015, 126, 3250-3250 | 3.6 | 0 | Citations (PDF) |
| 520 | Evaluation of the Revised International Staging System (R-ISS) in an Independent Cohort of Unselected Patients with Multiple MyelomaBlood, 2015, 126, 3045-3045 | 3.6 | 0 | Citations (PDF) |
| 521 | Prospective Evaluation of Blood Pressure Monitoring and Baroreceptor Reflex Sensitivity (BRS) in Patients with AL Amyloidosis: Prognostic and Pathophysiologic ImplicationsBlood, 2015, 126, 3054-3054 | 3.6 | 1 | Citations (PDF) |
| 522 | Validation of the Novel Criteria for the Definition of Symptomatic Myeloma: A Single Center Experience in 216 Patients with the Previous Diagnosis of Asymptomatic DiseaseBlood, 2015, 126, 4251-4251 | 3.6 | 0 | Citations (PDF) |
| 523 | Characterization of a PERK Kinase Inhibitor with Anti-Myeloma ActivityBlood, 2015, 126, 4188-4188 | 3.6 | 2 | Citations (PDF) |
| 524 | Real-World Prospective Evaluation of Different Geriatric Assessment Tools in Unselected Elderly Patients with Symptomatic MyelomaBlood, 2015, 126, 4242-4242 | 3.6 | 0 | Citations (PDF) |
| 525 | Profile of trebananib (AMG386) and its potential in the treatment of ovarian cancer | 1.5 | 8 | Citations (PDF) |
| 526 | Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis | 1.0 | 63 | Citations (PDF) |
| 527 | Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial | 1.0 | 38 | Citations (PDF) |
| 528 | Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents | 1.5 | 38 | Citations (PDF) |
| 529 | Treatment with bortezomib‐based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group | 5.2 | 64 | Citations (PDF) |
| 530 | The role of CXC-chemokine receptor CXCR2 and suppressor of cytokine signaling-3 (SOCS-3) in renal cell carcinoma | 2.1 | 22 | Citations (PDF) |
| 531 | Association of VEGF-A Splice Variant mRNA Expression With Outcome in Bevacizumab-Treated Patients With Metastatic Breast Cancer | 1.6 | 10 | Citations (PDF) |
| 532 | Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data | 16.1 | 278 | Citations (PDF) |
| 533 | Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer | 2.2 | 166 | Citations (PDF) |
| 534 | The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma | 1.0 | 5 | Citations (PDF) |
| 535 | International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation | 12.4 | 388 | Citations (PDF) |
| 536 | International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma | 16.1 | 4,608 | Citations (PDF) |
| 537 | The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: Final results on 205 patients of the Greek myeloma study group | 5.2 | 40 | Citations (PDF) |
| 538 | Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the Greek myeloma study group in 97 patients | 5.2 | 65 | Citations (PDF) |
| 539 | European Perspective on Multiple Myeloma Treatment Strategies in 2014 | 2.5 | 94 | Citations (PDF) |
| 540 | Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma | 26.4 | 782 | Citations (PDF) |
| 541 | Prognostic Significance of Cytoreductive Nephrectomy in Patients With Synchronous Metastases From Renal Cell Carcinoma Treated With First-Line Sunitinib: A European Multiinstitutional Study | 1.5 | 40 | Citations (PDF) |
| 542 | Less strength and more fractures for MGUS bonesBlood, 2014, 123, 603-604 | 3.6 | 2 | Citations (PDF) |
| 543 | Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensusBlood, 2014, 124, 1404-1411 | 3.6 | 163 | Citations (PDF) |
| 544 | Solitary bone plasmacytomas need to flowBlood, 2014, 124, 1209-1210 | 3.6 | 6 | Citations (PDF) |
| 545 | Fulvestrant and male breast cancer: a pooled analysis | 1.8 | 40 | Citations (PDF) |
| 546 | Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer | 1.5 | 32 | Citations (PDF) |
| 547 | Current treatment landscape for relapsed and/or refractory multiple myeloma | 54.3 | 197 | Citations (PDF) |
| 548 | Growth Differentiation Factor-15 in Patients with Light Chain (AL) Amyloidosis Has Independent Prognostic Significance and Adds Prognostic Information Related to Risk of Early Death and Renal OutcomesBlood, 2014, 124, 306-306 | 3.6 | 4 | Citations (PDF) |
| 549 | A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis | 3.6 | 11 | Citations (PDF) |
| 550 | Myeloma in the Octogenarians: Disease Characteristics and Clinical Outcomes in the Era of Modern Anti-Myeloma TherapyBlood, 2014, 124, 4738-4738 | 3.6 | 3 | Citations (PDF) |
| 551 | Efficacy and Safety Based on Duration of Treatment of Panobinostat Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma in the Phase 3 Panorama 1 StudyBlood, 2014, 124, 4742-4742 | 3.6 | 3 | Citations (PDF) |
| 552 | Three Drug Combinations Based on Bortezomib and Dexamethasone (VD) Backbone Improve Renal Function More Efficiently Than VD in Myeloma Patients with Severe Renal ImpairmentBlood, 2014, 124, 4769-4769 | 3.6 | 1 | Citations (PDF) |
| 553 | Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) with Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study | 3.6 | 15 | Citations (PDF) |
| 554 | Risk of Progression and Survival in Newly Diagnosed Multiple Myeloma Patients Non-Responsive to Bortezomib-Based Induction Therapy: an Observational Multicenter International StudyBlood, 2014, 124, 3488-3488 | 3.6 | 0 | Citations (PDF) |
| 555 | Elevated Involved Light Chains Discordant to the Increase of the Involved Heavy Chains Identifies a Subset of Multiple Myeloma Patients with Worse OutcomeBlood, 2014, 124, 2132-2132 | 3.6 | 0 | Citations (PDF) |
| 556 | High Bone Turnover Is Present in Patients with Primary Systemic (AL) Amyloidosis and Increased Osteoprotegerin Identifies Patients with Poor Survival within Mayo Stage 1 DiseaseBlood, 2014, 124, 2028-2028 | 3.6 | 0 | Citations (PDF) |
| 557 | Hemodynamic, Functional and Structural Markers of Vascular Involvement in Primary Systemic Light Chain (AL) AmyloidosisBlood, 2014, 124, 2029-2029 | 3.6 | 0 | Citations (PDF) |
| 558 | The Combination of Bortezomib and Lenalidomide (VR) Consolidation Post-ASCT, in the Absence of Dexamethasone and Bisphosphonates, Improves Response Rates and Bone Metabolism in Newly Diagnosed Patients with Multiple MyelomaBlood, 2014, 124, 3462-3462 | 3.6 | 0 | Citations (PDF) |
| 559 | Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) Is Able to Distinguish Diffuse from Normal MRI Pattern of Marrow Involvement in Patients with Multiple MyelomaBlood, 2014, 124, 3461-3461 | 3.6 | 1 | Citations (PDF) |
| 560 | Amplification of 1q21 Is Associated with Other High Risk Cytogenetic Abnormalities and Has No Independent Prognostic Significance in Patients Treated with Novel AgentsBlood, 2014, 124, 3464-3464 | 3.6 | 0 | Citations (PDF) |
| 561 | Renal Outcomes in Patients with AL Amyloidosis: Evaluation of Prognostic Factors and Impact of Therapy with Novel AgentsBlood, 2014, 124, 2130-2130 | 3.6 | 0 | Citations (PDF) |
| 562 | Genetic Factors Related with Early Onset of Osteonecrosis of the Jaw in Patients with Multiple Myeloma Under Zoledronic Acid TherapyBlood, 2014, 124, 2115-2115 | 3.6 | 0 | Citations (PDF) |
| 563 | Impact of Renal Impairment (RI) on Outcomes after Treatment (Tx) with Lenalidomide and Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): First Trial ResultsBlood, 2014, 124, 2112-2112 | 3.6 | 1 | Citations (PDF) |
| 564 | Translating Findings of Proteasome Inhibitors Effects from the in VivoDrosophila Experimental Model to Humans: The Paradigm of the Molecular-Cellular Responses to Bortezomib and CarfilzomibBlood, 2014, 124, 4814-4814 | 3.6 | 0 | Citations (PDF) |
| 565 | Circulating Adamts-13 Is Reduced in Patients with Waldenstrom's Macroglobulinemia and Is Associated with Increased IgM Levels and Features of the Disease but Not with the Increased Levels of Von Willebrand FactorBlood, 2014, 124, 5741-5741 | 3.6 | 0 | Citations (PDF) |
| 566 | Solitary bone plasmacytoma and extramedullary plasmacytoma | 3.0 | 109 | Citations (PDF) |
| 567 | Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials | 2.1 | 28 | Citations (PDF) |
| 568 | Metachronous appearance of second malignancies in medullary thyroid carcinoma (MTC) patients: a diagnostic challenge and brief review of the literature | 1.8 | 4 | Citations (PDF) |
| 569 | How lenalidomide is changing the treatment of patients with multiple myeloma | 3.5 | 25 | Citations (PDF) |
| 570 | Proteasome Inhibitor Therapy for Waldenström's Macroglobulinemia | 0.8 | 7 | Citations (PDF) |
| 571 | Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma | 0.7 | 48 | Citations (PDF) |
| 572 | International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease | 12.4 | 334 | Citations (PDF) |
| 573 | Angiogenesis-Related Pathways in the Pathogenesis of Ovarian Cancer | 3.2 | 126 | Citations (PDF) |
| 574 | Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial | 16.1 | 780 | Citations (PDF) |
| 575 | Proteasome dysfunction inDrosophilasignals to an Nrf2-dependent regulatory circuit aiming to restore proteostasis and prevent premature aging | 4.8 | 109 | Citations (PDF) |
| 576 | Current treatments for renal failure due to multiple myeloma | 1.9 | 29 | Citations (PDF) |
| 577 | Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)Blood, 2013, 122, 3276-3282 | 3.6 | 192 | Citations (PDF) |
| 578 | Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myelomaBlood, 2013, 121, 318-328 | 3.6 | 126 | Citations (PDF) |
| 579 | Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study | 16.1 | 231 | Citations (PDF) |
| 580 | A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma | 1.7 | 119 | Citations (PDF) |
| 581 | Re‐evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents | 1.6 | 55 | Citations (PDF) |
| 582 | Ambulatory blood pressure monitoring in acute stroke | 0.3 | 18 | Citations (PDF) |
| 583 | Prevalence of BRCA1 Mutations in Familial and Sporadic Greek Ovarian Cancer Cases | 1.5 | 30 | Citations (PDF) |
| 584 | Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma | 1.5 | 36 | Citations (PDF) |
| 585 | Tobacco smoking and risk of multiple myeloma: A meta‐analysis of 40 observational studies | 2.8 | 29 | Citations (PDF) |
| 586 | Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide‐based regimens | 5.2 | 44 | Citations (PDF) |
| 587 | The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD‐EPI‐CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD‐EPI‐CysC equations? | 1.5 | 45 | Citations (PDF) |
| 588 | Optimal use of bisphosphonates in patients with multiple myelomaBlood, 2013, 121, 3325-3328 | 3.6 | 44 | Citations (PDF) |
| 589 | A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosisBlood, 2013, 121, 3420-3427 | 3.6 | 493 | Citations (PDF) |
| 590 | Elevated Von Willebrand Factor Antigen Serum Levels Are Associated With Poor Prognosis In Patients With Symptomatic Waldenstrom’s MacroglobulinemiaBlood, 2013, 122, 1860-1860 | 3.6 | 2 | Citations (PDF) |
| 591 | Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) Improves Health-Related Quality Of Life (HRQoL) Vs High-Dose Dexamethasone (HiDEX) In Relapsed Refractory Multiple Myeloma (RRMM) Patients Enrolled In MM-003 Phase 3 Randomized TrialBlood, 2013, 122, 2939-2939 | 3.6 | 3 | Citations (PDF) |
| 592 | MM-003 Phase 3 Study Of Pomalidomide In Combination With Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM): POM + Lodex Is Beneficial For Elderly Patients (> 65 Years of Age)Blood, 2013, 122, 3198-3198 | 3.6 | 2 | Citations (PDF) |
| 593 | Final Analysis, Cytogenetics, Long-Term Treatment, and Long-Term Survival In MM-003, A Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM)Blood, 2013, 122, 408-408 | 3.6 | 10 | Citations (PDF) |
| 594 | Patient Outcomes By Prior Therapies and Depth Of Response: Analysis Of MM-003, a Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM)Blood, 2013, 122, 686-686 | 3.6 | 2 | Citations (PDF) |
| 595 | Angiogenic cytokines profile in smoldering multiple myeloma: No difference compared to MGUS but altered compared to symptomatic myeloma | 0.9 | 7 | Citations (PDF) |
| 596 | Prognostic Significance of ESR1 Gene Amplification, mRNA/Protein Expression and Functional Profiles in High-Risk Early Breast Cancer: A Translational Study of the Hellenic Cooperative Oncology Group (HeCOG) | 1.5 | 15 | Citations (PDF) |
| 597 | Estimated Glomerular Filtration Rate Calculated By The CKD-EPI Formula Has Improved Prognostic Ability Over MDRD Formula In Patients With Newly Diagnosed, Symptomatic, Multiple Myeloma: Analysis In 1937 PatientsBlood, 2013, 122, 1867-1867 | 3.6 | 1 | Citations (PDF) |
| 598 | Disease-Associated Changes In The Repair Efficiency Of Double Strand Breaks Affect Melphalan Sensitivity Of The Bone Marrow Plasma Cells and Correlate With The Clinical Outcome Of Anti-Myeloma TherapyBlood, 2013, 122, 3723-3723 | 3.6 | 4 | Citations (PDF) |
| 599 | Genetic Variations In TLR-4/TIRAP Genes Influence Response To IMiDs-Based Regimens and Conventional Chemotherapy In Patients With Multiple MyelomaBlood, 2013, 122, 1861-1861 | 3.6 | 1 | Citations (PDF) |
| 600 | Efficacy and Safety Of Pomalidomide Plus Low-Dose Dexamethasone In Advanced Multiple Myeloma: Results Of Randomized Phase 2 and 3 Trials (MM-002/MM-003)Blood, 2013, 122, 3185-3185 | 3.6 | 0 | Citations (PDF) |
| 601 | Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone with or Without Radiotherapy in Primary Mediastinal Large B-Cell Lymphoma: The Emerging Standard of Care | 2.5 | 122 | Citations (PDF) |
| 602 | European Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses | 2.5 | 48 | Citations (PDF) |
| 603 | Replication Protein A in Nonearly Ovarian Adenocarcinomas | 1.1 | 17 | Citations (PDF) |
| 604 | Ambulatory blood pressure monitoring in acute stroke | 0.3 | 3 | Citations (PDF) |
| 605 | Novel Therapeutic Agents for the Management of Patients with Multiple Myeloma and Renal Impairment | 4.5 | 42 | Citations (PDF) |
| 606 | Dose-Dense Sequential Adjuvant Chemotherapy With Epirubicin, Paclitaxel and CMF Versus Epirubicin, Cmf and Weekly Docetaxel or Paclitaxel Followed by Trastuzumab for One Year in Patients With Early Breast Cancer | 8.0 | 2 | Citations (PDF) |
| 607 | A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomideBlood, 2012, 119, 2764-2767 | 3.6 | 148 | Citations (PDF) |
| 608 | When a little aspirin may be enoughBlood, 2012, 119, 905-906 | 3.6 | 5 | Citations (PDF) |
| 609 | A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosisBlood, 2012, 119, 5384-5390 | 3.6 | 90 | Citations (PDF) |
| 610 | VWF, WM, and angiogenesis: is there a link?Blood, 2012, 120, 3163-3164 | 3.6 | 2 | Citations (PDF) |
| 611 | Sclerostin: a possible target for the management of cancer-induced bone disease | 2.8 | 35 | Citations (PDF) |
| 612 | Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma | 0.9 | 21 | Citations (PDF) |
| 613 | Development and validation of a PCR‐based assay for the selection of patients more likely to benefit from therapeutic treatment with alkylating drugs | 1.5 | 12 | Citations (PDF) |
| 614 | How to Manage Neutropenia in Multiple Myeloma | 0.8 | 48 | Citations (PDF) |
| 615 | Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment | 6.0 | 16 | Citations (PDF) |
| 616 | Evolving Chemotherapy Options for the Treatment of Myeloma Kidney: A 40-Year Perspective | 1.8 | 2 | Citations (PDF) |
| 617 | Prevention and Treatment of Myeloma Bone Disease | 2.2 | 11 | Citations (PDF) |
| 618 | Differential Response of Immunohistochemically Defined Breast Cancer Subtypes to Anthracycline-Based Adjuvant Chemotherapy with or without Paclitaxel | 1.5 | 54 | Citations (PDF) |
| 619 | Increased expression of cyclin‐D1 on trephine bone marrow biopsies independently predicts for shorter overall survival in patients with multiple myeloma treated with novel agents | 5.2 | 10 | Citations (PDF) |
| 620 | Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: A single center experience on 228 patients | 5.2 | 94 | Citations (PDF) |
| 621 | Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma | 26.4 | 733 | Citations (PDF) |
| 622 | Multiple myeloma in octogenarians: Clinical features and outcome in the novel agent era | 1.5 | 35 | Citations (PDF) |
| 623 | Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: Report of 2 cases with clinical implications | 0.4 | 65 | Citations (PDF) |
| 624 | VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2 | 2.8 | 167 | Citations (PDF) |
| 625 | Pomalidomide in Combination with Low-Dose Dexamethasone: Demonstrates a Significant Progression Free Survival and Overall Survival Advantage, in Relapsed/Refractory MM: A Phase 3, Multicenter, Randomized, Open-Label StudyBlood, 2012, 120, LBA-6-LBA-6 | 3.6 | 16 | Citations (PDF) |
| 626 | Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3Blood, 2011, 117, 4701-4705 | 3.6 | 413 | Citations (PDF) |
| 627 | Advances in Imaging and the Management of Myeloma Bone Disease | 12.4 | 120 | Citations (PDF) |
| 628 | Increased Serum Lactate Dehydrongenase Should Be Included Among the Variables That Define Very-High-Risk Multiple Myeloma | 0.8 | 43 | Citations (PDF) |
| 629 | Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens | 1.0 | 29 | Citations (PDF) |
| 630 | Adjusting for Patient Crossover in Clinical Trials Using External Data: A Case Study of Lenalidomide for Advanced Multiple Myeloma | 1.0 | 11 | Citations (PDF) |
| 631 | Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone | 0.8 | 59 | Citations (PDF) |
| 632 | Prognostication of the High-Risk WM Patient | 0.8 | 2 | Citations (PDF) |
| 633 | Management of advanced bladder cancer in patients with impaired renal function | 1.5 | 11 | Citations (PDF) |
| 634 | Treatment of relapsed and refractory multiple myeloma in the era of novel agents | 6.0 | 68 | Citations (PDF) |
| 635 | Intermittent Docetaxel Chemotherapy in Patients With Castrate-resistant Prostate Cancer | 1.1 | 22 | Citations (PDF) |
| 636 | Report of the long-term efficacy of two cycles of adjuvant bleomycin/etoposide/cisplatin in patients with stage I testicular nonseminomatous germ-cell tumors (NSGCT): A risk adapted protocol of the Hellenic Cooperative Oncology Group | 0.8 | 12 | Citations (PDF) |
| 637 | The Mediterranean Diet in Cancer Prevention: A Review | 1.2 | 88 | Citations (PDF) |
| 638 | Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: The impact of inflammatory process and oxidative stress | 1.9 | 69 | Citations (PDF) |
| 639 | The role of the cell adhesion molecules (integrins / cadherins) in prostate cancer | 1.3 | 15 | Citations (PDF) |
| 640 | Systemic Chemotherapy with Pemetrexed and Cisplatin for Malignant Peritoneal Mesothelioma: A Single Institution Experience | 1.1 | 17 | Citations (PDF) |
| 641 | Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenström macroglobulinemiaBlood, 2011, 117, 2918-2923 | 3.6 | 42 | Citations (PDF) |
| 642 | Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1Blood, 2011, 117, 4691-4695 | 3.6 | 974 | Citations (PDF) |
| 643 | Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2Blood, 2011, 117, 4696-4700 | 3.6 | 299 | Citations (PDF) |
| 644 | International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantationBlood, 2011, 117, 6063-6073 | 3.6 | 297 | Citations (PDF) |
| 645 | Bortezomib for AL amyloidosis: moving forwardBlood, 2011, 118, 827-828 | 3.6 | 20 | Citations (PDF) |
| 646 | Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)Blood, 2011, 118, 4519-4529 | 3.6 | 338 | Citations (PDF) |
| 647 | Characterization of haematological parameters with bortezomib–melphalan–prednisone versus melphalan–prednisone in newly diagnosed myeloma, with evaluation of long‐term outcomes and risk of thromboembolic events with use of erythropoiesis‐stimulating agents: analysis of the VISTA trial | 1.7 | 14 | Citations (PDF) |
| 648 | Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study | 1.5 | 139 | Citations (PDF) |
| 649 | Emerging therapies for the treatment of relapsed or refractory multiple myeloma | 1.5 | 71 | Citations (PDF) |
| 650 | Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan–prednisone vs. melphalan–prednisone in the phase III VISTA trial in multiple myeloma | 1.5 | 83 | Citations (PDF) |
| 651 | Short progression‐free survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agent‐based therapy | 1.5 | 9 | Citations (PDF) |
| 652 | The repair of melphalan-induced DNA adducts in the transcribed strand of active genes is subject to a strong polarity effect | 1.2 | 9 | Citations (PDF) |
| 653 | Consensus on the utility of bone markers in the malignant bone disease setting | 3.5 | 91 | Citations (PDF) |
| 654 | Interaction between the skeletal and immune systems in cancer: mechanisms and clinical implications | 3.1 | 28 | Citations (PDF) |
| 655 | Olive oil intake is inversely related to cancer prevalence: a systematic review and a meta-analysis of 13800 patients and 23340 controls in 19 observational studies | 3.5 | 245 | Citations (PDF) |
| 656 | A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: A Hellenic Cooperative Oncology Group study | 4.4 | 47 | Citations (PDF) |
| 657 | Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease | 3.5 | 23 | Citations (PDF) |
| 658 | No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years | 5.2 | 45 | Citations (PDF) |
| 659 | Lenalidomide-associated pneumonitis in patients with plasma cell dyscrasias | 5.2 | 16 | Citations (PDF) |
| 660 | Outcomes after adjuvant chemotherapy in the treatment of high‐risk urothelial carcinoma of the upper urinary tract (UUT‐UC) | 2.7 | 108 | Citations (PDF) |
| 661 | Relapse of Ovarian Cancer With Bone Marrow Infiltration and Concurrent Emergence of Therapy-Related Acute Myeloid Leukemia: A Case Report | 12.4 | 2 | Citations (PDF) |
| 662 | Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective | 2.5 | 27 | Citations (PDF) |
| 663 | Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study | 3.7 | 715 | Citations (PDF) |
| 664 | Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study | 2.3 | 10 | Citations (PDF) |
| 665 | Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial | 1.8 | 49 | Citations (PDF) |
| 666 | Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisoneBlood, 2010, 116, 3743-3750 | 3.6 | 102 | Citations (PDF) |
| 667 | Prechemotherapy Serum Levels of CD105, Transforming Growth Factor β2, and Vascular Endothelial Growth Factor Are Associated With Prognosis in Patients With Advanced Epithelial Ovarian Cancer Treated With Cytoreductive Surgery and Platinum-Based Chemotherapy | 2.2 | 9 | Citations (PDF) |
| 668 | Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model | 2.1 | 28 | Citations (PDF) |
| 669 | Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment | 1.5 | 46 | Citations (PDF) |
| 670 | High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents | 1.5 | 132 | Citations (PDF) |
| 671 | The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function | 2.7 | 119 | Citations (PDF) |
| 672 | Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem‐cell transplantation: Results of a single institution, randomized phase 2 trial | 5.2 | 49 | Citations (PDF) |
| 673 | High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents | 0.7 | 27 | Citations (PDF) |
| 674 | Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma | 0.7 | 56 | Citations (PDF) |
| 675 | Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH) | 0.7 | 63 | Citations (PDF) |
| 676 | Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents | 0.7 | 66 | Citations (PDF) |
| 677 | Monoclonal gammopathy of undetermined significance: a consensus statement | 1.7 | 108 | Citations (PDF) |
| 678 | The role of high-dose chemotherapy in the treatment of testicular cancer | 1.0 | 1 | Citations (PDF) |
| 679 | Immune Response in Ovarian Cancer: How Is the Immune SystemInvolved in Prognosis and Therapy: Potential for Treatment Utilization | 1.6 | 48 | Citations (PDF) |
| 680 | Smoldering (Asymptomatic) Multiple Myeloma: Current Diagnostic Criteria, New Predictors of Outcome, and Follow-Up Recommendations | 12.4 | 107 | Citations (PDF) |
| 681 | Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective | 2.5 | 86 | Citations (PDF) |
| 682 | Clinical Characteristics and Outcome of Primary Systemic Light-Chain Amyloidosis in Greece | 0.8 | 18 | Citations (PDF) |
| 683 | Bortezomib as a Treatment Option in Patients With Waldenström Macroglobulinemia | 0.8 | 21 | Citations (PDF) |
| 684 | Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group | 12.4 | 391 | Citations (PDF) |
| 685 | Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: A randomized placebo-controlled study | 1.9 | 59 | Citations (PDF) |
| 686 | Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues | 16.1 | 201 | Citations (PDF) |
| 687 | Intravenous pamidronate for myeloma bone disease: can the dose be lowered? | 16.1 | 0 | Citations (PDF) |
| 688 | The role of high-dose chemotherapy in the treatment of testicular cancer | 0.0 | 0 | Citations (PDF) |
| 689 | Pathogenesis and management of myeloma bone disease | 1.5 | 45 | Citations (PDF) |
| 690 | Could Rigorous Diagnosis and Management of Hypertension Reduce Cardiac Events in Patients With Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors? | 12.4 | 20 | Citations (PDF) |
| 691 | Phenoxodiol, an anticancer isoflavene, induces immunomodulatory effects in vitro and in vivo | 2.4 | 33 | Citations (PDF) |
| 692 | Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma | 1.5 | 105 | Citations (PDF) |
| 693 | Somatic mutations of adenomatous polyposis coli gene and nuclear b‐catenin accumulation have prognostic significance in invasive urothelial carcinomas: Evidence for Wnt pathway implication | 2.8 | 59 | Citations (PDF) |
| 694 | Anti-tumor immune response in ovarian cancer: clinical implications, prognostic significance and potential for novel treatment strategies | 1.7 | 1 | Citations (PDF) |
| 695 | Targeted therapies in multiple myeloma | 2.5 | 31 | Citations (PDF) |
| 696 | Periodic Therapeutic Plasma Exchange in Patients With Moderate to Severe Chronic Myasthenia Gravis Non‐Responsive to Immunosuppressive Agents: An Eight Year Follow‐Up | 0.6 | 20 | Citations (PDF) |
| 697 | Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma | 3.8 | 38 | Citations (PDF) |
| 698 | Update on the use of erythropoiesis-stimulating agents (ESAs) for the management of anemia of multiple myeloma and lymphoma | 6.0 | 12 | Citations (PDF) |
| 699 | Reversibility of Renal Impairment in Patients With Multiple Myeloma Treated With Bortezomib-Based Regimens: Identification of Predictive Factors | 1.8 | 105 | Citations (PDF) |
| 700 | International prognostic scoring system for Waldenström macroglobulinemiaBlood, 2009, 113, 4163-4170 | 3.6 | 414 | Citations (PDF) |
| 701 | Treatment of Relapsed/Refractory Multiple Myeloma | 2.3 | 51 | Citations (PDF) |
| 702 | Study of T Lymphocytes Infiltrating Peritoneal Metastases in Advanced Ovarian Cancer | 2.2 | 34 | Citations (PDF) |
| 703 | Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis | 2.3 | 20 | Citations (PDF) |
| 704 | Full Dose of Lenalidomide for 12 Months Followed by a Lower Maintenance Dose Improves Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma.Blood, 2009, 114, 2874-2874 | 3.6 | 4 | Citations (PDF) |
| 705 | Neutropenia Is a Predictable and Early Event in Affected Patients with Relapsed/Refractory Multiple Myeloma Treated with Lenalidomide in Combination with Dexamethasone.Blood, 2009, 114, 2879-2879 | 3.6 | 8 | Citations (PDF) |
| 706 | Bortezomib Plus Melphalan–Prednisone Continues to Demonstrate a Survival Benefit Vs Melphalan–Prednisone in the Phase III VISTA Trial in Previously Untreated Multiple Myeloma After 3 Years' Follow-up and Extensive Subsequent Therapy Use.Blood, 2009, 114, 3859-3859 | 3.6 | 3 | Citations (PDF) |
| 707 | Lenalidomide plus Dexamethasone Has Similar Tolerability and Efficacy in Treatment of Relapsed/Refractory Multiple Myeloma Patients with or without History of Neuropathy.Blood, 2009, 114, 3873-3873 | 3.6 | 8 | Citations (PDF) |
| 708 | Primary Therapy of Waldnestrom's Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone and Rituximab (BDR): A Phase II Study of the European Myeloma Network.Blood, 2009, 114, 2886-2886 | 3.6 | 0 | Citations (PDF) |
| 709 | Therapeutic Plasma Exchange Combined With Immunomodulating Agents in Secondary Progressive Multiple Sclerosis Patients | 0.6 | 8 | Citations (PDF) |
| 710 | Prognostic value of kallikrein‐related peptidase 6 protein expression levels in advanced ovarian cancer evaluated by automated quantitative analysis (AQUA) | 2.9 | 25 | Citations (PDF) |
| 711 | Prognostic and Predictive Factors in Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel and Estramustine: A Single Institution Experience | 1.1 | 20 | Citations (PDF) |
| 712 | Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma | 26.4 | 1,850 | Citations (PDF) |
| 713 | Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposureBlood, 2008, 112, 4445-4451 | 3.6 | 168 | Citations (PDF) |
| 714 | Wegener’s Granulomatosis Presenting as a Renal Mass | 1.1 | 21 | Citations (PDF) |
| 715 | Biweekly Doxorubicin/Ketoconazole as Second-Line Treatment in Docetaxel-Resistant, Hormone-Refractory Prostate Cancer | 1.1 | 2 | Citations (PDF) |
| 716 | Carboplatin and Paclitaxel versus Cisplatin, Paclitaxel and Doxorubicin for first-line chemotherapy of Advanced Ovarian Cancer: A Hellenic Cooperative Oncology Group (HeCOG) study | 2.8 | 19 | Citations (PDF) |
| 717 | Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw | 16.1 | 138 | Citations (PDF) |
| 718 | Natural History of Osteonecrosis of the Jaw in Patients With Multiple Myeloma | 12.4 | 144 | Citations (PDF) |
| 719 | Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working GroupBlood, 2008, 111, 4039-4047 | 3.6 | 217 | Citations (PDF) |
| 720 | Endovascular stenting for the management of port-a-cath associated superior vena cava syndrome | 0.7 | 12 | Citations (PDF) |
| 721 | The evolving role of lenalidomide in the treatment of hematologic malignancies | 1.9 | 47 | Citations (PDF) |
| 722 | Pulsed cyclophosphamide, thalidomide and dexamethasone regimen for previously treated patients with multiple myeloma: Long term follow up and disease control after subsequent treatments | 1.0 | 16 | Citations (PDF) |
| 723 | Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma | 26.4 | 1,405 | Citations (PDF) |
| 724 | Two Cycles of Etoposide/Cisplatin Cured All Patients with Stage I Testicular Seminoma: Risk-Adapted Protocol of the Hellenic Cooperative Oncology Group | 1.1 | 5 | Citations (PDF) |
| 725 | Management of Relapsed and Relapsed Refractory Myeloma | 1.5 | 8 | Citations (PDF) |
| 726 | Thalidomide in the treatment of multiple myeloma | 1.6 | 20 | Citations (PDF) |
| 727 | Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ratio of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity | 1.7 | 38 | Citations (PDF) |
| 728 | Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma | 2.3 | 29 | Citations (PDF) |
| 729 | Squamous Cell Esophageal Carcinoma as a Second Primary Malignancy in a Woman with Epithelial Ovarian Cancer | 1.5 | 0 | Citations (PDF) |
| 730 | Treatment of Waldenstrom’s Macroglobulinemia | 3.0 | 18 | Citations (PDF) |
| 731 | The Combination of Bortezomib, Doxorubicin, and Dexamethasone (PAD) Is an Effective Regimen for High Risk, Newly Diagnosed, Patients with Multiple Myeloma, Reduces Bone Resorption and Normalizes Angiopoietin-1 to Angiopoietin-2 Ratio.Blood, 2007, 110, 3596-3596 | 3.6 | 2 | Citations (PDF) |
| 732 | High Bone Turnover and Increased Angiogenesis Cytokines in Patients with POEMS Syndrome.Blood, 2007, 110, 3525-3525 | 3.6 | 0 | Citations (PDF) |
| 733 | Primary gastrointestinal non-Hodgkin's lymphoma: A clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG) | 1.0 | 146 | Citations (PDF) |
| 734 | Extranodal non-Hodgkin's lymphoma presenting as an abdominal wall mass. A case report and review of the literature | 1.0 | 12 | Citations (PDF) |
| 735 | Update on treatment recommendations from the Third International Workshop on Waldenstrom's MacroglobulinemiaBlood, 2006, 107, 3442-3446 | 3.6 | 151 | Citations (PDF) |
| 736 | Survivin and glycodelin transcriptional activity in node-positive early breast cancer: mRNA expression of two key regulators of cell survival | 1.8 | 16 | Citations (PDF) |
| 737 | Update on Recommendations for Assessing Response from the Third International Workshop on Waldenström's Macroglobulinemia | 1.8 | 109 | Citations (PDF) |
| 738 | Non-Hodgkin's Lymphoma of the Renal Pelvis | 1.8 | 9 | Citations (PDF) |
| 739 | Preferential in vivo DNA repair of melphalan-induced damage in human genes is greatly affected by the local chromatin structure | 1.8 | 25 | Citations (PDF) |
| 740 | Concurrent development of testicular seminoma and choriocarcinoma of the superior mediastinum, presented as cervical mass: a case report and implications about pathogenesis of germ-cell tumours | 2.4 | 7 | Citations (PDF) |
| 741 | Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose–dense sequential adjuvant chemotherapy | 1.8 | 45 | Citations (PDF) |
| 742 | Advanced stage clear-cell epithelial ovarian cancer: The Hellenic cooperative oncology group experience | 2.3 | 136 | Citations (PDF) |
| 743 | Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group | 2.1 | 12 | Citations (PDF) |
| 744 | The combination of gemcitabine and carboplatin as first‐line treatment in patients with advanced urothelial carcinoma | 2.7 | 81 | Citations (PDF) |
| 745 | Evaluation of the Prognostic Value of Cellular Inhibitor of Apoptosis Protein in Epithelial Ovarian Cancer Using Automated Quantitative Protein Analysis | 0.6 | 11 | Citations (PDF) |
| 746 | Rituximab therapy in monoclonal IgM-related neuropathies | 1.0 | 53 | Citations (PDF) |
| 747 | Bcl-2 protein and DNA ploidy in renal cell carcinoma: Do they affect patient prognosis? | 1.5 | 11 | Citations (PDF) |
| 748 | Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: a phase-II trial by the Hellenic Cooperative Oncology Group | 1.5 | 24 | Citations (PDF) |
| 749 | Multiple myeloma in elderly patients: prognostic factors and outcome | 1.5 | 52 | Citations (PDF) |
| 750 | Familial female and male germ cell cancer. A new syndrome? | 2.3 | 13 | Citations (PDF) |
| 751 | Clinicopathological features of ovarian carcinosarcomas: a single institution experience | 2.3 | 39 | Citations (PDF) |
| 752 | Advanced stage mucinous epithelial ovarian cancer: The Hellenic Cooperative Oncology Group experience | 2.3 | 143 | Citations (PDF) |
| 753 | Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin | 2.7 | 59 | Citations (PDF) |
| 754 | Extent of Damage and Repair in the p53 Tumor-Suppressor Gene After Treatment of Myeloma Patients With High-Dose Melphalan and Autologous Blood Stem-Cell Transplantation Is Individualized and May Predict Clinical Outcome | 12.4 | 27 | Citations (PDF) |
| 755 | Multifocal Extranodal Non‐Hodgkin Lymphoma: A Clinicopathologic Study of 37 Cases in Greece, a Hellenic Cooperative Oncology Group Study | 2.5 | 25 | Citations (PDF) |
| 756 | Thalidomide and immunomodulatory drugs in the treatment of cancer | 2.4 | 28 | Citations (PDF) |
| 757 | Neoadjuvant chemotherapy in invasive bladder cancer | 1.5 | 2 | Citations (PDF) |
| 758 | Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk Factors | 12.4 | 1,036 | Citations (PDF) |
| 759 | Predictive Factors for Response to Rituximab in Waldenström's Macroglobulinemia | 1.8 | 38 | Citations (PDF) |
| 760 | Waldenström's macroglobulinemia | 1.6 | 44 | Citations (PDF) |
| 761 | Diagnosis and Management of Waldenstrom's Macroglobulinemia | 12.4 | 236 | Citations (PDF) |
| 762 | Treatment of Relapsed/Refractory Multiple Myeloma with Thalidomide-based Regimens: Identification of Prognostic Factors | 1.0 | 15 | Citations (PDF) |
| 763 | Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma | 0.6 | 131 | Citations (PDF) |
| 764 | Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS) | 1.7 | 98 | Citations (PDF) |
| 765 | Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study | 2.3 | 46 | Citations (PDF) |
| 766 | Monoclonal gammopathy of undetermined significance (MGUS) in patients with solid tumors: effects of chemotherapy on the monoclonal protein | 1.0 | 6 | Citations (PDF) |
| 767 | The International Staging System for Multiple Myeloma is Applicable in Symptomatic Waldenstrom's Macroglobulinemia | 1.0 | 37 | Citations (PDF) |
| 768 | Treatment of Waldenstrom's Macroglobulinemia with Rituximab: Prognostic Factors for Response and Progression | 1.0 | 39 | Citations (PDF) |
| 769 | Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study | 1.1 | 37 | Citations (PDF) |
| 770 | Adverse effects of thalidomide administration in patients with neoplastic diseases | 1.4 | 127 | Citations (PDF) |
| 771 | Primary Mediastinal Large B-Cell Lymphoma | 1.1 | 7 | Citations (PDF) |
| 772 | 2-chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia | 2.8 | 108 | Citations (PDF) |
| 773 | Defining Waldenstrom's macroglobulinemia | 2.8 | 21 | Citations (PDF) |
| 774 | Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia | 2.8 | 917 | Citations (PDF) |
| 775 | Expansion of CD8+
T cells that express low levels of the B cell-specific molecule CD20 in patients with multiple myeloma | 1.7 | 8 | Citations (PDF) |
| 776 | Treatment of Waldenstrom's Macroglobulinemia with the Combination of Fludarabine and Cyclophosphamide | 1.0 | 57 | Citations (PDF) |
| 777 | Angiogenesis in human cancer: implications in cancer therapy | 2.4 | 43 | Citations (PDF) |
| 778 | Thalidomide in relapsed/refractory multiple myeloma: pivotal trials conducted outside the United States | 2.3 | 11 | Citations (PDF) |
| 779 | High Dose Therapy with Autologous Stem Cell Transplantation for Solitary Bone Plasmacytoma Complicated by Local Relapse or Isolated Distant Recurrence | 1.0 | 12 | Citations (PDF) |
| 780 | Treatment of Plasma Cell Dyscrasias With Thalidomide and Its Derivatives | 12.4 | 118 | Citations (PDF) |
| 781 | Myocardial adrenergic denervation in patients with primary (AL) amyloidosis | 2.6 | 12 | Citations (PDF) |
| 782 | Rituximab in combination with CNOP chemotherapy in patients with previously untreated indolent non-Hodgkin's lymphoma | 0.6 | 13 | Citations (PDF) |
| 783 | Primary Treatment of Low-grade Non-Hodgkin's Lymphoma with the Combination of Fludarabine and Mitoxantrone: A Phase II Study of the Hellenic Cooperative Oncology Group | 1.0 | 12 | Citations (PDF) |
| 784 | Cadmium content in foodstuffs from the Greek market | 2.3 | 64 | Citations (PDF) |
| 785 | A Phase III Study of 5-Fluorouracil Versus 5-Fluorouracil Plus Interferon Alpha 2b Versus 5-Fluorouracil Plus Leucovorin in Patients With Advanced Colorectal Cancer | 1.1 | 10 | Citations (PDF) |
| 786 | Extended Rituximab Therapy for Previously Untreated Patients with Waldenström's Macroglobulinemia | 1.8 | 72 | Citations (PDF) |
| 787 | A prospective study of pulmonary function in patients treated with paclitaxel and carboplatin | 2.7 | 68 | Citations (PDF) |
| 788 | Combination of Ifosfamide, Paclitaxel, and Cisplatin for the Treatment of Metastatic and Recurrent Carcinoma of the Uterine Cervix: A Phase II Study of the Hellenic Cooperative Oncology Group | 2.3 | 34 | Citations (PDF) |
| 789 | Title is missing! | 1.5 | 34 | Citations (PDF) |
| 790 | Treatment of Waldenstrom’s Macroglobulinemia With Thalidomide | 12.4 | 125 | Citations (PDF) |
| 791 | B-Cell Kinase Lyn Deficiency in Patients with Systemic Lupus Erythematosus | 0.9 | 139 | Citations (PDF) |
| 792 | Impact of complete remission with intensive therapy in patients with responsive multiple myeloma | 1.9 | 120 | Citations (PDF) |
| 793 | Randomized trial of ?-interferon or dexamethasone as maintenance treatment for multiple myeloma | 5.2 | 36 | Citations (PDF) |
| 794 | Paclitaxel, cisplatin, and epirubicin first-line chemotherapy in Stage III and IV ovarian carcinoma | 2.7 | 19 | Citations (PDF) |
| 795 | Non-cryopreserved peripheral blood progenitor cells collected by a single very large-volume leukapheresis: A simplified and effective procedure for support of high-dose chemotherapy | 1.6 | 14 | Citations (PDF) |
| 796 | Paclitaxel and Cisplatin in Advanced or Recurrent Carcinoma of the Endometrium: Long-Term Results of a Phase II Multicenter Study | 2.3 | 85 | Citations (PDF) |
| 797 | Solitary plasmacytoma of bone and asymptomatic multiple myelomaBlood, 2000, 96, 2037-2044 | 3.6 | 375 | Citations (PDF) |
| 798 | Waldenström’s Macroglobulinemia: Clinical Features, Complications, and Management | 12.4 | 320 | Citations (PDF) |
| 799 | Cushing syndrome as the presenting feature of metastatic Leydig cell tumor of the testis | 1.1 | 10 | Citations (PDF) |
| 800 | Successful Conservative Treatment of Neutropenic Enterocolitis Complicating Taxane-Based Chemotherapy | 1.1 | 56 | Citations (PDF) |
| 801 | Treatment of Pancreatic Cancer With Docetaxel and Granulocyte Colony-Stimulating Factor: A Multicenter Phase II Study | 12.4 | 80 | Citations (PDF) |
| 802 | Phase II Trial of Paclitaxel and Cisplatin in Metastatic and Recurrent Carcinoma of the Uterine Cervix | 12.4 | 106 | Citations (PDF) |
| 803 | Hodgkin’s disease with lymphocyte predominance: long-term results based on current histopathologic criteria | 1.3 | 17 | Citations (PDF) |
| 804 | MR imaging of complex tail-gut cysts | 1.1 | 40 | Citations (PDF) |
| 805 | SOLITARY PLASMACYTOMA OF BONE AND EXTRAMEDULLARY PLASMACYTOMA | 1.5 | 184 | Citations (PDF) |
| 806 | WALDENSTRÖM'S MACROGLOBULINEMIA | 1.5 | 43 | Citations (PDF) |
| 807 | Bone Lesions with Soft-Tissue Mass: Magnetic Resonance Imaging Diagnosis of Lymphomatous Involvement of the Bone Marrow Versus Multiple Myeloma and Bone Metastases | 1.0 | 37 | Citations (PDF) |
| 808 | Prognostic value of cytogenetics in multiple myeloma | 1.7 | 108 | Citations (PDF) |
| 809 | The prevalence of bcl-2, p53, and ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates | 1.7 | 109 | Citations (PDF) |
| 810 | Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxel | 1.1 | 51 | Citations (PDF) |
| 811 | Very Late Relapse of Hodgkin's Disease After 24 Years of Complete Remission | 1.0 | 3 | Citations (PDF) |
| 812 | Treatment of Langerhans Cell Histiocytosis with 2 Chlorodeoxyadenosine | 1.0 | 25 | Citations (PDF) |
| 813 | Primary parotid lymphoma: the effect of international prognostic index on outcome | 1.0 | 28 | Citations (PDF) |
| 814 | Cisplatin, Ifosfamide, Methotrexate and Vinblastine Combination Chemotherapy for Metastatic Urothelial Cancer | 3.1 | 13 | Citations (PDF) |
| 815 | Late relapse of nonseminomatous germ cell tumor of the testis: Successful treatment with salvage chemotherapy alone | 1.1 | 5 | Citations (PDF) |
| 816 | Oral estramustine and oral etoposide for hormone-refractory prostate cancer | 1.1 | 81 | Citations (PDF) |
| 817 | Primary Ovarian Non-Hodgkin's Lymphoma: Outcome after Treatment with Combination Chemotherapy | 2.3 | 122 | Citations (PDF) |
| 818 | A Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of metastatic carcinoma of the uterine cervix | 2.7 | 29 | Citations (PDF) |
| 819 | Cisplatin, Ifosfamide, Methotrexate and Vinblastine Combination Chemotherapy for Metastatic Urothelial Cancer | 3.1 | 2 | Citations (PDF) |
| 820 | Prunart Renal Lymphoma: A Clinical and Radiological Study | 3.1 | 49 | Citations (PDF) |
| 821 | Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma | 26.4 | 1,055 | Citations (PDF) |
| 822 | Prunart Renal Lymphoma | 3.1 | 0 | Citations (PDF) |
| 823 | 9Complications and supportive therapy of multiple myeloma | 1.0 | 5 | Citations (PDF) |
| 824 | Dosing of thioTEPA for myeloablative therapy | 1.3 | 32 | Citations (PDF) |
| 825 | VAD-Cyclosporine Therapy for VAD-Resistant Multiple Myeloma | 1.0 | 8 | Citations (PDF) |
| 826 | Waldenström Macroglobulinemia Presenting as a Renal or Perirenal Mass: Clinical and Radiographic Features | 1.0 | 23 | Citations (PDF) |
| 827 | A Phase 1-11 Study of High-Dose Thiotepa, Busulfan and Cyclophosphamide as a Preparative Regimen for Autologous Transplantation for Malignant Lymphoma | 1.0 | 25 | Citations (PDF) |
| 828 | Rising Serum Lactate Dehydrogenase Often Caused by Granulocyte-or Granulocyte-Macrophage Colony Stimulating Factor and not Tumor Progression in Patients with Lymphoma or Myeloma | 1.0 | 22 | Citations (PDF) |
| 829 | Primary Lymphoma of the Prostate: Good Outcome with Doxorubicin-Based Combination Chemotherapy | 3.1 | 96 | Citations (PDF) |
| 830 | Myeloablative therapy for primary resistant multiple myeloma | 2.7 | 10 | Citations (PDF) |
| 831 | Intensive Sequential Therapy for VAD-Resistant Multiple Myeloma | 1.0 | 5 | Citations (PDF) |
| 832 | The Treatment of Multiple Myeloma | 26.4 | 387 | Citations (PDF) |
| 833 | Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for marrow transplantation: Risk factors for early regimen-related toxicity | 1.0 | 32 | Citations (PDF) |
| 834 | Allogeneic bone marrow transplantation for leukemia following piperazinedione and fractionated total body irradiation | 5.2 | 7 | Citations (PDF) |
| 835 | The Expanding Role of Fludarabine in Hematologic Malignancies | 1.0 | 26 | Citations (PDF) |
| 836 | Regression of gastric lymphoma of mucosa-associated lymphoid tissue with antibiotic therapy for Helicobacter pylori | 0.9 | 122 | Citations (PDF) |
| 837 | Calcitriol Production in Hypercalcemic and Normocalcemic Patients with Non-Hodgkin Lymphoma | 7.3 | 138 | Citations (PDF) |
| 838 | Cyclophosphamide and etoposide therapy with GM‐CSF for VAD‐resistant multiple myeloma | 1.7 | 37 | Citations (PDF) |
| 839 | Risk of disease progression in asymptomatic multiple myeloma | 1.4 | 156 | Citations (PDF) |
| 840 | Fludarabine therapy in Waldenström's macroglobulinemia | 1.4 | 117 | Citations (PDF) |
| 841 | Treatment of Waldenstrom Macroglobulinemia with 2-Chlorodeoxyadenosine | 7.3 | 111 | Citations (PDF) |
| 842 | Extramedullary Plasmacytoma of the Pancreas | 1.1 | 8 | Citations (PDF) |
| 843 | Solitary Plasmacytoma of Bone and Asymptomatic Multiple Myeloma | 1.5 | 48 | Citations (PDF) |
| 844 | Allogeneic bone marrow transplantation for hematological malignancies following etoposide, cyclophosphamide, and fractionated total body irradiation | 5.2 | 17 | Citations (PDF) |
| 845 | Paraneoplastic Cushing's syndrome as an adverse prognostic factor in patients who die early with small cell lung cancer | 2.7 | 86 | Citations (PDF) |
| 846 | Predictive factors for effective salvage therapy of nonseminomatous germ cell tumors of testis | 1.1 | 4 | Citations (PDF) |
| 847 | Breast cancer and second primary ovarian cancer in dermatomyositis | 2.3 | 15 | Citations (PDF) |
| 848 | High Serum Lactate Dehydrogenase Level as a Marker for Drug Resistance and Short Survival in Multiple Myeloma | 7.3 | 194 | Citations (PDF) |
| 849 | An effective acute graft-vs.-host disease prophylaxis with minidose methotrexate, cyclosporine, and single-dose methylprednisolone | 5.2 | 8 | Citations (PDF) |
| 850 | Prophylaxis of cytomegalovirus infection with ganciclovir in allogeneic marrow transplantation | 1.5 | 23 | Citations (PDF) |
| 851 | Efficacy and safety of elotuzumab for the treatment of multiple myeloma | 1.6 | 5 | Citations (PDF) |
| 852 | Managing complications secondary to Waldenström’s macroglobulinemia | 1.5 | 0 | Citations (PDF) |
| 853 | Title is missing! 0 | | 2 | Citations (PDF) |
| 854 | Lymphadenopathy is an independent prognostic factor for patients with Waldenström macroglobulinaemia | 1.7 | 0 | Citations (PDF) |
| 855 | Determinants of 15‐Year Progression‐Free Survival in Multiple Myeloma; Real‐World Data From a Single Institution | 5.2 | 9 | Citations (PDF) |
| 856 | Practical Guidance on Clinical Management of Belantamab Mafodotin‐Associated Ocular Events | 5.2 | 12 | Citations (PDF) |
| 857 | Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN study | 3.7 | 0 | Citations (PDF) |
| 858 | Genomic landscape of IgM-MGUS and patients with stable or progressive asymptomatic Waldenström macroglobulinemia | 3.6 | 5 | Citations (PDF) |
| 859 | Current experiences with teclistamab in patients with multiple myeloma and renal impairment | 1.5 | 4 | Citations (PDF) |
| 860 | SOHO State of the Art Updates and Next Questions | Treatment of Myeloma Early Relapse: Non-CAR T Cell | 0.8 | 0 | Citations (PDF) |
| 861 | Remission of recurrent systemic capillary leak syndrome associated with monoclonal gammopathy following anti-myeloma treatment – a case report and literature review | 1.0 | 0 | Citations (PDF) |
| 862 | Circulating tumor cells by Next Generation Flow Cytometry as a new prognostic biomarker for patients with asymptomatic monoclonal gammopathies | 4.1 | 2 | Citations (PDF) |
| 863 | Cold pressor test and paradoxical blood pressure reduction in light chain amyloidosis | 2.6 | 0 | Citations (PDF) |
| 864 | Cardiovascular Safety of Carfilzomib in Patients with Multiple Myeloma | 0.8 | 0 | Citations (PDF) |
| 865 | Epigenetics in Ovarian Cancer: A Review of Current Knowledge and Future Perspectives | 2.5 | 7 | Citations (PDF) |
| 866 | Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network | 0.6 | 11 | Citations (PDF) |
| 867 | Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myeloma | 4.1 | 2 | Citations (PDF) |
| 868 | The Hippo Pathway in Metaplastic Breast Carcinoma: Prognostic Significance and Therapeutic Implications | 2.3 | 0 | Citations (PDF) |
| 869 | Can Exercise Training Improve the Quality of Life and Physical Function in Multiple Myeloma Patients?: Discussing the Progression of the Training Stimulus | 1.4 | 1 | Citations (PDF) |
| 870 | Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide‐refractory multiple myeloma: Subgroup analysis of the
BOSTON
trial | 1.7 | 1 | Citations (PDF) |
| 871 | Real-world outcomes of first-line enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma. | 12.4 | 0 | Citations (PDF) |
| 872 | Efficacy of chemotherapy after PARP inhibitor progression in ovarian cancer: A large real-world cohort. | 12.4 | 0 | Citations (PDF) |
| 873 | Case Report: Not all signet rings are of gastric origin: a case of lobular breast carcinoma metastatic to the stomach | 1.7 | 0 | Citations (PDF) |
| 874 | Safety profile of chimeric antigen receptor T‐cell therapy in relapsed/refractory multiple myeloma: A systematic review and meta‐analysis of proportions from clinical trials | 1.7 | 0 | Citations (PDF) |
| 875 | Signals in Peripheral Blood: Tracking Redox Status and DNA Damage Response During the Progression of Multiple Myeloma | 3.2 | 0 | Citations (PDF) |
| 876 | Myeloma Progression Without Osteolysis: Rethinking Whole‐Body Low‐Dose
CT
Criteria for Bone Disease | 5.2 | 0 | Citations (PDF) |
